RM
301.45
.A66
1997
Nov
Suppl

CUMULATIVE
SUPPLEMENT 11
JAN'97-NOV'97



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1997

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 11

NOVEMBER 1997

CONTENTS

Library Use Only

RM301.45 .A66 1997 Nov Suppl

Approved drug products with
therapeutic equivalence
C:355661 M:174736 O:12937927

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
LEMMON CO SUB TAG PHARMACEUTICAL INC (LEMMON)	BIOCRAFT LABORATORIES INC (BIOCRAFT) **THEN CHANGED TO** TEVA PHARMACEUTICALS USA (TEVA)
REXAR PHARMACAL (REXAR)	SHIRE RICHWOOD INC (SHIRE RICHWOOD)
RICHWOOD PHARMACEUTICAL CO INC (RICHWOOD PHARM)	SHIRE RICHWOOD INC (SHIRE RICHWOOD)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCALS CORP (NOVARTIS)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493	9533	9501
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	2420 (25.5%)
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	6970 (73.3%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	6587 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	383 (4.0%)
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)	114 (1.2%)	111 (1.2%)
NEW MOLECULAR ENTITIES APPROVED	--	6	8	14
NUMBER OF APPLICANTS	650	662	682	701

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

ACARBOSE

TABLET; ORAL
PRECOSE

> DLT >		BAYER	25MG	N20482 004 MAY 29, 1997
> DLT >				
> ADD >		@	25MG	N20482 004 MAY 29, 1997
> ADD >				

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

		BUCET		
AB		MALLINCKRODT	650MG;50MG	N88991 001 JUN 28, 1985
		BUTALBITAL AND ACETAMINOPHEN		
AB		GRAHAM DM	650MG;50MG	N88991 001 JUN 28, 1985
		CONTEN		
AB		GRAHAM DM	650MG;50MG	N89405 001 MAY 15, 1990
		TENCON		
AB		MALLINCKRODT	650MG;50MG	N89405 001 MAY 15, 1990

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB		GRAHAM DM	325MG;50MG;40MG	N88743 001 JUL 18, 1985
AB			325MG;50MG;40MG	N88765 001 MAR 27, 1985
AB			325MG;50MG;40MG	N89023 001 JUN 19, 1985
AB			325MG;50MG;40MG	N89067 001 APR 19, 1985
AB			325MG;50MG;40MG	N89102 001 JUN 19, 1985
	@		325MG;50MG;40MG	N88743 001 JUL 18, 1985
	@		325MG;50MG;40MG	N88765 001 MAR 27, 1985
	@		325MG;50MG;40MG	N89067 001 APR 19, 1985
		FEMCET		
AB		MALLINCKRODT	325MG;50MG;40MG	N89102 001 JUN 19, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

		TRIAD		
AB		MALLINCKRODT	325MG;50MG;40MG	N89023 001 JUN 19, 1985
		TABLET; ORAL		
		REPAN		
AB		GRAHAM DM	325MG;50MG;40MG	N87804 001 JAN 24, 1985
AB		MALLINCKRODT	325MG;50MG;40MG	N87804 001 JAN 24, 1985

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA		MIKART	356.4MG;30MG;16MG	N40109 001 AUG 26, 1997
		DHC PLUS		
AA	+	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

> ADD >	AA	DURAMED	300MG;15MG	N40223 001 NOV 18, 1997
> ADD >				
> ADD >	AA		300MG;30MG	N40223 002 NOV 18, 1997
> ADD >				
> ADD >	AA		300MG;60MG	N40223 003 NOV 18, 1997

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL
ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA	+	GRAHAM DM	500MG;5MG	N87336 001 JUL 08, 1982
AA			500MG;5MG	N88956 001 JUL 19, 1985
		HYDROCET		
AA		GRAHAM DM	500MG;5MG	N89006 001 AUG 09, 1985

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCET

AA		MALLINCKRODT	500MG;5MG	N89006 001 AUG 09, 1985

LORCET-HD

AA	+	MALLINCKRODT	500MG;5MG	N87336 001 JUL 08, 1982

ZYDONE

AA		MALLINCKRODT	500MG;5MG	N88956 001 JUL 19, 1985

TABLET; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA		GRAHAM DM	500MG;5MG	N87722 001 JUL 09, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	BARR	500MG;5MG	N88577 001 DEC 21, 1984
AA		EON	500MG;5MG	N40149 001 JAN 27, 1997
AA			750MG;7.5MG	N40149 002 JAN 27, 1997
AA		HALSEY	500MG;5MG	N40236 001 SEP 25, 1997
> ADD > AA			650MG;7.5MG	N40240 002 NOV 26, 1997
> ADD > AA			650MG;10MG	N40240 001 NOV 26, 1997
AA			750MG;7.5MG	N40236 002 SEP 25, 1997
AA		PEACHTREE	500MG;10MG	N40210 001 AUG 13, 1997
AA		VINTAGE PHARMS	500MG;2.5MG	N40144 002 APR 25, 1997
AA			650MG;7.5MG	N40155 001 APR 14, 1997
AA		WATSON LABS	500MG;10MG	N40148 002 FEB 14, 1997

HYDROCODONE BITARTRATE W/ ACETAMINOPHEN

AA		BARR	500MG;5MG	N88577 001 DEC 21, 1984

LORTAB

AA	+	GRAHAM DM	500MG;10MG	N40100 001 JAN 26, 1996
AA		MALLINCKRODT	500MG;5MG	N87722 001 JUL 09, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

LORTAB

AA	+	UCB	500MG;10MG	N40100 001 JAN 26, 1996
			325MG;5MG	N40099 001 JUN 25, 1997

NORCO

	+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ROYCE LABS	500MG;5MG	N40234 001 OCT 30, 1997

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ROYCE LABS	325MG;5MG	N40171 001 OCT 30, 1997

PERCOCET

AA	+	DUPONT MERCK	325MG;5MG	N85106 002
AA	+	ENDO PHARMS	325MG;5MG	N85106 002

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB		VINTAGE PHARMS	650MG;100MG	N74843 001 FEB 12, 1997

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB		TARO	125MG	N40195 001 MAY 28, 1997
AB			250MG	N40195 002 MAY 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	ABBOTT	**EQ 500MG BASE/VIAL**	**N40108 001**	OCT 30, 1995
AP	SANOFI WINTHROP	**EQ 500MG BASE/VIAL**	**N40108 001**	OCT 30, 1995

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; AURICULAR (OTIC)

	TRIDESILON		
@	BAYER	2%;0.05%	N17914 001

SOLUTION/DROPS; OTIC

	TRIDESILON		
	BAYER	2%;0.05%	N17914 001

ACYCLOVIR

CAPSULE; ORAL

		ACYCLOVIR		
AB		AESGEN	**200MG**	**N74833 001** APR 22, 1997
AB		APOTHECON	**200MG**	**N74889 001** OCT 31, 1997
>ADD> **AB**		COPLEY PHARM	**200MG**	**N74914 001** NOV 26, 1997
>ADD> **AB**		ESI LEDERLE	**200MG**	**N74872 001** APR 22, 1997
AB		LEK PHARM	**200MG**	**N74750 001** APR 22, 1997
AB		LEMMON	**200MG**	**N74828 001** APR 22, 1997
AB		MYLAN	**200MG**	**N74727 001** APR 22, 1997
AB		NOVOPHARM	**200MG**	**N74578 001** APR 22, 1997
AB		PUREPAC PHARM	**200MG**	**N74906 001** AUG 26, 1997
AB		ROXANE	**200MG**	**N74570 002** APR 22, 1997
AB		TEVA	**200MG**	**N74828 001** APR 22, 1997
AB		ZENITH GOLDLINE	**200MG**	**N74674 001** APR 22, 1997

ACYCLOVIR

CAPSULE; ORAL

		ZOVIRAX		
AB	+	GLAXO WELLCOME	**200MG**	**N18828 001** JAN 25, 1985

SUSPENSION; ORAL

		ACYCLOVIR		
AB		ALPHARMA	**200MG/5ML**	**N74738 001** APR 28, 1997
		ZOVIRAX		
AB	+	GLAXO WELLCOME	**200MG/5ML**	**N19909 001** DEC 22, 1989

TABLET; ORAL

		ACYCLOVIR		
>ADD> **AB**		AESGEN	**400MG**	**N74946 001** NOV 19, 1997
>ADD> **AB**			**800MG**	**N74946 002** NOV 19, 1997
>ADD> **AB**		APOTHECON	**400MG**	**N74891 001** OCT 31, 1997
>ADD> **AB**			**800MG**	**N74891 002** OCT 31, 1997
AB		ESI LEDERLE	**400MG**	**N74834 001** APR 24, 1997
AB			**800MG**	**N74834 002** APR 24, 1997
AB		LEK PHARM	**400MG**	**N74658 001** APR 22, 1997
AB			**800MG**	**N74658 002** APR 22, 1997
AB		NOVOPHARM	**400MG**	**N74556 002** APR 22, 1997
AB			**800MG**	**N74556 003** APR 22, 1997
	+		200MG	N74556 001 APR 22, 1997
AB		PUREPAC PHARM	**400MG**	**N74870 001** JUN 05, 1997
AB			**800MG**	**N74870 002** JUN 05, 1997
AB		ZENITH GOLDLINE	**400MG**	**N74836 001** APR 22, 1997
AB			**800MG**	**N74836 002** APR 22, 1997
		ZOVIRAX		
AB		GLAXO WELLCOME	**400MG**	**N20089 001** APR 30, 1991

ACYCLOVIR

TABLET; ORAL
ZOVIRAX

AB	+ GLAXO WELLCOME	800MG	N20089 002	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	ABBOTT	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
AP		EQ 500MG BASE/VIAL	N74758 001	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74758 002	APR 22, 1997
AP	BEDFORD	EQ 500MG BASE/VIAL	N74596 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74596 001	APR 22, 1997
AP	ESI LEDERLE	EQ 500MG BASE/VIAL	N74913 001	OCT 15, 1997
AP		EQ 1GM BASE/VIAL	N74913 002	OCT 15, 1997
+	FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
AP	GENSIA	EQ 500MG BASE/VIAL	N74969 001	AUG 26, 1997
AP		EQ 1GM BASE/VIAL	N74969 002	AUG 26, 1997
AP	SANOFI	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997
	ZOVIRAX			
AP	+ GLAXO WELLCOME	EQ 500MG BASE/VIAL	N18603 001	OCT 22, 1982
AP	+	EQ 1GM BASE/VIAL	N18603 002	JUN 29, 1989

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL

AB	ALPHARMA	0.09MG/INH	N73045 001	AUG 19, 1997

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	NEPHRON	EQ 0.083% BASE	N74880 001	SEP 17, 1997

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX

	MERCK	EQ 5MG BASE	N20560 003	APR 25, 1997

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

AP	PHARMACIA AND UPJOHN	0.005MG/VIAL	N20379 003	JUN 27, 1996
AP		0.01MG/VIAL	N20379 001	JUL 06, 1995
AP		0.02MG/VIAL	N20379 002	JUL 06, 1995
AP	+	0.04MG/VIAL	N20379 004	MAY 19, 1997

ALPROSTADIL

INJECTABLE; INJECTION

	CAVERJECT			
	PHARMACIA AND UPJOHN	0.005MG/ML	N20755 001	OCT 31, 1997
		0.01MG/ML	N20755 002	OCT 01, 1997
+		0.02MG/ML	N20755 003	OCT 01, 1997
	EDEX			
AP	SCHWARZ PHARMA	0.005MG/VIAL	N20649 001	JUN 12, 1997
AP		0.01MG/VIAL	N20649 002	JUN 12, 1997
AP		0.02MG/VIAL	N20649 003	JUN 12, 1997
AP +		0.04MG/VIAL	N20649 004	JUN 12, 1997

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

> DLT >	SYMADINE			
> DLT > AB	SOLVAY	100MG	N71000 001	SEP 04, 1986
> DLT >				
> ADD >	@	100MG	N71000 001	SEP 04, 1986
> ADD >				

TABLET; ORAL

SYMMETREL			
@ DUPONT MERCK	100MG	N18101 001	
@ ENDO PHARMS	100MG	N18101 001	

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	ABBOTT	EQ 250MG BASE/ML	N64098 001	JUN 26, 1995
AP		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995
AP	ELKINS SINN	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
	@	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001	JUN 26, 1995
AP		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	EQ 500MG BASE/100ML	N64146 001	APR 02, 1997

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 5%			
ABBOTT	5%	N19438 002	APR 03, 1986
@	5%	N19438 002	APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 001	SEP 12, 1988
@	3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 001	SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19714 002	SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

@ ABBOTT 4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 002 SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 004 SEP 12, 1988

@ 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 004 SEP 12, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004 NOV 07, 1988

5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 003 SEP 12, 1988

@ 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004 NOV 07, 1988

@ 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19714 003 SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 009 MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT — 3.5%;25GM/100ML — N19505 002 NOV 07, 1986

ABBOTT — 3.5%;25GM/100ML — N19713 006 SEP 09, 1988

@ — 3.5%;25GM/100ML — N19505 002 NOV 07, 1986

@ — 3.5%;25GM/100ML — N19713 006 SEP 09, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT — 3.5%;5GM/100ML — N19506 001 NOV 07, 1986

ABBOTT — 3.5%;5GM/100ML — N19713 002 SEP 09, 1988

@ — 3.5%;5GM/100ML — N19506 001 NOV 07, 1986

@ — 3.5%;5GM/100ML — N19713 002 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT — 4.25%;10GM/100ML — N19713 001 SEP 09, 1988

@ — 4.25%;10GM/100ML — N19713 001 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT — 4.25%;20GM/100ML — N19713 004 SEP 09, 1988

@ — 4.25%;20GM/100ML — N19713 004 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT — 4.25%;25GM/100ML — N19504 002 NOV 07, 1986

ABBOTT — 4.25%;25GM/100ML — N19713 005 SEP 09, 1988

@ — 4.25%;25GM/100ML — N19504 002 NOV 07, 1986

@ — 4.25%;25GM/100ML — N19713 005 SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT — 5%;25GM/100ML — N19713 003 SEP 09, 1988

@ — 5%;25GM/100ML — N19713 003 SEP 09, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE — 2.75%;10% — N20734 002 SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE — 2.75%;25GM/100ML — N20734 005 SEP 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE — 2.75%;5GM/100ML — N20734 001 SEP 29, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008 SEP 29, 1997 > DLT >

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010 SEP 29, 1997 > DLT >

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011 SEP 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007 SEP 29, 1997 > ADD >

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;10GM/100ML N20734 014 SEP 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;15GM/100ML N20734 015 SEP 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;20GM/100ML N20734 016 SEP 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;25GM/100ML N20734 017 SEP 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;35GM/100ML N20734 018 SEP 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML N19682 003 NOV 01, 1988

@ 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML N19682 003 NOV 01, 1988

@ 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML N19712 002 SEP 08, 1988

ABBOTT 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML;205MG/100ML N19712 002 SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19712 001 SEP 08, 1988

@ 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19712 001 SEP 08, 1988

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP * SEARLE **25MG/ML** **N87243 001 MAY 24, 1982**

@ 25MG/ML N87243 001 MAY 24, 1982

AMINOPHYLLINE

AP ELKINS SINN **25MG/ML** **N87239 001**

AMINOPHYLLINE

INJECTABLE; INJECTION

		AMINOPHYLLINE		
AP	+	ELKINS SINN	**25MG/ML**	**N87239 001**
AP		PHARMA SERVE NY	**25MG/ML**	**N87387 001**
				JUN 03, 1983
	@		25MG/ML	N87387 001
				JUN 03, 1983

TABLET; ORAL

		AMINOPHYLLINE		
BD		HALSEY	100MG	N84674 001
	@		100MG	N84674 001

TABLET, EXTENDED RELEASE; ORAL

		PHYLLOCONTIN		
	+	PURDUE FREDERICK	225MG	N86760 001
	@		225MG	N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HCL		
BP		HALSEY	10MG	N85923 001
BP			50MG	N85925 001
BP			75MG	N85926 001
				MAY 20, 1983
BP			100MG	N85927 001
				MAY 20, 1983
	@		10MG	N85923 001
	@		50MG	N85925 001
	@		75MG	N85926 001
				MAY 20, 1983
	@		100MG	N85927 001
				MAY 20, 1983
		AMITRIPTYLINE HYDROCHLORIDE		
AB		VINTAGE PHARMS	**10MG**	**N40218 001**
				SEP 11, 1997
AB			**25MG**	**N40218 002**
				SEP 11, 1997
AB			**50MG**	**N40218 003**
				SEP 11, 1997
AB			**75MG**	**N40218 004**
				SEP 11, 1997
AB			**100MG**	**N40218 005**
				SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HYDROCHLORIDE		
AB		VINTAGE PHARMS	**150MG**	**N40218 006**
				SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

		LIMBITROL		
AB		ICN	**EQ 12.5MG BASE;5MG**	**N16949 001**
AB		ROCHE	**EQ 12.5MG BASE;5MG**	**N16949 001**
		LIMBITROL DS		
AB	+	ICN	**EQ 25MG BASE;10MG**	**N16949 002**
AB	+	ROCHE	**EQ 25MG BASE;10MG**	**N16949 002**

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

		ETRAFON-A		
BP		SCHERING	10MG;4MG	N14713 002
	@		10MG;4MG	N14713 002
		PERPHENAZINE AND AMITRIPTYLINE HCL		
	@	ZENITH GOLDLINE	10MG;2MG	N70935 001
				SEP 11, 1986
	@		10MG;4MG	N70937 001
				SEP 11, 1986
	@		25MG;2MG	N70936 001
				SEP 11, 1986
	@		25MG;4MG	N70938 001
				SEP 11, 1986
	@		50MG;4MG	N70939 001
				SEP 12, 1986
AB		ZENITH LABS	**10MG;2MG**	**N70935 001**
				SEP 11, 1986
AB			**10MG;4MG**	**N70937 001**
				SEP 11, 1986
AB			**25MG;2MG**	**N70936 001**
				SEP 11, 1986
AB			**25MG;4MG**	**N70938 001**
				SEP 11, 1986
AB			**50MG;4MG**	**N70939 001**
				SEP 12, 1986

AMOXICILLIN

CAPSULE; ORAL

		AMOXIL		
AB	+	SMITHKLINE BEECHAM	250MG	N50459 001
AB			250MG	N62216 001
AB	+		250MG	N62216 001
AB	+		500MG	N50459 002
AB			500MG	N62216 004
AB	+		500MG	N62216 004
	@		250MG	N50459 001
	@		500MG	N50459 002

POWDER FOR RECONSTITUTION; ORAL

		AMOXIL		
AB	+	SMITHKLINE BEECHAM	125MG/5ML	N50460 001
AB			125MG/5ML	N62226 001
AB	+		125MG/5ML	N62226 001
AB	+		250MG/5ML	N50460 002
AB	+		50MG/ML	N50460 005
AB			250MG/5ML	N62226 002
AB	+		250MG/5ML	N62226 002
AB			50MG/ML	N62226 005
AB	+		50MG/ML	N62226 005
	@		125MG/5ML	N50460 001
	@		250MG/5ML	N50460 002
	@		50MG/ML	N50460 005
		LAROTID		
AB		SMITHKLINE BEECHAM	50MG/ML	N50460 006
	@		50MG/ML	N50460 006

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

		ADDERALL 10		
		RICHWOOD PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007 FEB 13, 1996
		SHIRE RICHWOOD	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007 FEB 13, 1996
		ADDERALL 20		
	+	RICHWOOD PHARM	5MG;5MG;5MG;5MG	N11522 008 FEB 13, 1996
		SHIRE RICHWOOD	5MG;5MG;5MG;5MG	N11522 008 FEB 13, 1996
		ADDERALL 30		
	+	SHIRE RICHWOOD	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010 MAY 12, 1997

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

		ADDERALL 5		
		SHIRE RICHWOOD	1.25MG;1.25MG;1.25MG; 1.25MG	N11522 009 MAY 12, 1997

AMPHOTERICIN B

INJECTABLE; INJECTION

		AMPHOTERICIN B		
AP		ABBOTT	50MG/VIAL	N64141 001 DEC 23, 1996
AP		SANOFI WINTHROP	50MG/VIAL	N64141 001 DEC 23, 1996

INJECTABLE, LIPOSOMAL; INJECTION

		AMBISOME		
	+	FUJISAWA	50MG/VIAL	N50740 001 AUG 11, 1997

OINTMENT; TOPICAL

		FUNGIZONE		
	+	APOTHECON	3%	N50313 001
	@		3%	N50313 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

		AMPICILLIN TRIHYDRATE		
	@	ZENITH GOLDLINE	EQ 250MG BASE	N60765 001
	@		EQ 500MG BASE	N60765 002
AB		ZENITH LABS	EQ 250MG BASE	N60765 001
AB			EQ 500MG BASE	N60765 002

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

		AGRYLIN		
		ROBERTS LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
	+		EQ 1MG BASE	N20333 002 MAR 14, 1997

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL
VALPIN 50

>_DLT_>	@ DUPONT MERCK	50MG		N13428 001
>_ADD_>	@ ENDO PHARMS	50MG		N13428 001

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

+	GENSIA	0.05MG/ML	N20420 001 SEP 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO

+	WYETH AYERST	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997
+		10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

+	SAVAGE LABS	650MG;50MG	N88305 001 OCT 13, 1983
@		650MG;50MG	N88305 001 OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL COMPOUND

@	ZENITH GOLDLINE	325MG;50MG;40MG		N85441 002 OCT 31, 1984
AB	ZENITH LABS	325MG;50MG;40MG		**N85441 002** **OCT 31, 1984**

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

@	PAR PHARM	385MG;30MG;25MG	N71642 001 JUN 23, 1987

ORPHENGESIC FORTE

@	PAR PHARM	770MG;60MG;50MG	N71643 001 JUN 23, 1987

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65

@	ZENITH GOLDLINE	389MG;32.4MG;65MG	N83077 002 DEC 07, 1984
AA	ZENITH LABS	389MG;32.4MG;65MG	**N83077 002** DEC 07, 1984

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
CODOXY

AA	HALSEY	325MG;4.5MG;0.38MG		**N87464 001** **JUL 01, 1982**
@		325MG;4.5MG;0.38MG		N87464 001 JUL 01, 1982

PERCODAN

AA	+ DUPONT MERCK	325MG;4.5MG;0.38MG		**N07337 006**
AA	+ ENDO PHARMS	325MG;4.5MG;0.38MG		N07337 006

PERCODAN-DEMI

AA	+ DUPONT MERCK	325MG;2.25MG;0.19MG		**N07337 005**
AA	+ ENDO PHARMS	325MG;2.25MG;0.19MG		N07337 005

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MUTUAL PHARM	25MG		**N74499 001** JUL 30, 1997
AB	SIDMAK LABS NJ	25MG		**N74101 001** JUL 17, 1997
AB		50MG		**N74101 002** JUL 17, 1997
AB		100MG		**N74101 003** JUL 17, 1997

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

		ATENOLOL AND CHLORTHALIDONE		
AB		SIDMAK LABS NJ	50MG;25MG	N74107 001 SEP 24, 1997
AB			100MG;25MG	N74107 002 SEP 24, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

		ATRACURIUM BESYLATE		
AP		ABBOTT	10MG/ML	N74633 001 DEC 23, 1996
AP		BEDFORD	10MG/ML	N74901 001 JUL 18, 1997
AP		ESI LEDERLE	10MG/ML	N74824 001 SEP 30, 1997
AP		FAULDING	10MG/ML	N74740 001 MAR 28, 1997
AP		GENSIA	10MG/ML	N74784 001 JUN 11, 1997
AP		OHMEDA	10MG/ML	N74753 001 JAN 23, 1997
		ATRACURIUM BESYLATE PRESERVATIVE FREE		
AP		ABBOTT	10MG/ML	N74633 001 DEC 23, 1996
AP			10MG/ML	N74639 001 MAR 25, 1997
AP		BEDFORD	10MG/ML	N74900 001 JUL 18, 1997
AP		ESI LEDERLE	10MG/ML	N74825 001 SEP 30, 1997
AP		FAULDING	10MG/ML	N74741 001 MAR 28, 1997
AP		OHMEDA	10MG/ML	N74768 001 JAN 23, 1997
		TRACRIUM		
AP	+	GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983
AP	+		10MG/ML	N18831 002 JUN 20, 1985
		TRACRIUM PRESERVATIVE FREE		
AP	+	GLAXO WELLCOME	10MG/ML	N18831 001 NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

		DIPHENOXYLATE HCL AND ATROPINE SULFATE		
AA		ROXANE	0.025MG;2.5MG	N86057 001
	@		0.025MG;2.5MG	N86057 001
		DIPHENOXYLATE HCL W/ ATROPINE SULFATE		
AA		ICN	0.025MG;2.5MG	N87195 001 FEB 16, 1982
	@		0.025MG;2.5MG	N87195 001 FEB 16, 1982
AA		KV PHARM	0.025MG;2.5MG	N85659 001
	@		0.025MG;2.5MG	N85659 001
	@	ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001
AA		ZENITH LABS	0.025MG;2.5MG	N86727 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		ATROPINE AND DEMEROL		
	+	ABBOTT	0.4MG/ML;50MG/ML	N87853 001 NOV 26, 1982
	+		0.4MG/ML;75MG/ML	N87847 001 NOV 26, 1982
	+		0.4MG/ML;100MG/ML	N87848 001 NOV 26, 1982
	+	STERLING WINTHROP	0.4MG/ML;50MG/ML	N87853 001 NOV 26, 1982
	+		0.4MG/ML;75MG/ML	N87847 001 NOV 26, 1982
	+		0.4MG/ML;100MG/ML	N87848 001 NOV 26, 1982

AURANOFIN

CAPSULE; ORAL

		RIDAURA		
	+	CONNECTICS	3MG	N18689 001 MAY 24, 1985
	+	SMITHKLINE BEECHAM	3MG	N18689 001 MAY 24, 1985

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION
ZITHROMAX
+ PFIZER — EQ 500MG BASE/VIAL — N50733 001 JAN 30, 1997

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN
+ BAYER — EQ 2GM BASE/VIAL — N50562 001 SEP 03, 1982
+ — EQ 3GM BASE/VIAL — N50562 002 SEP 03, 1982
+ — EQ 4GM BASE/VIAL — N50562 003 SEP 03, 1982
@ — EQ 2GM BASE/VIAL — N50562 001 SEP 03, 1982
@ — EQ 3GM BASE/VIAL — N50562 002 SEP 03, 1982
@ — EQ 4GM BASE/VIAL — N50562 003 SEP 03, 1982 >ADD< >ADD<

BACITRACIN

INJECTABLE; INJECTION
BACIIM
AP PHARMA TEK — 50,000 UNITS/VIAL — N64153 001 MAY 09, 1997

BACITRACIN
AP + PHARMACIA AND UPJOHN — 50,000 UNITS/VIAL — N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
CORTISPORIN
+ GLAXO WELLCOME — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984
+ MONARCH PHARMS — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ
BN GLAXO WELLCOME — EQ 0.042MG DIPROP/SPRAY — N19389 001 JUL 27, 1987
BN + — EQ 0.042MG DIPROP/SPRAY — N19389 001 JUL 27, 1987

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL
EMETE-CON
+ ROBERIG — EQ 100MG BASE — N16818 006
@ — EQ 100MG BASE — N16818 006

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
AB CLAY PARK — EQ 0.05% BASE — N74579 001 NOV 26, 1997

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
@ ALPHARMA — EQ 0.05% BASE — N71085 001 FEB 03, 1987
AB NMC — EQ 0.05% BASE — N71085 001 FEB 03, 1987

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB FOUGERA — EQ 0.1% BASE — N18861 001 AUG 31, 1983
AB + — EQ 0.1% BASE — N18861 001 AUG 31, 1983

VALISONE
AB + SCHERING — EQ 0.1% BASE — N16322 001
EQ 0.01% BASE — N16322 002
@ — EQ 0.01% BASE — N16322 002
@ — EQ 0.1% BASE — N16322 001

LOTION; TOPICAL
BETAMETHASONE VALERATE
AB FOUGERA — EQ 0.1% BASE — N18866 001 AUG 31, 1983

BETAMETHASONE VALERATE

LOTION; TOPICAL

		BETAMETHASONE VALERATE		
AB	+	FOUGERA	**EQ 0.1% BASE**	**N18866 001 AUG 31, 1983**
		VALISONE		
AB	+	SCHERING	**EQ 0.1% BASE**	**N16932 001**
	@		EQ 0.1% BASE	N16932 001

OINTMENT; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	**EQ 0.1% BASE**	**N18865 001 AUG 31, 1983**
AB	+		**EQ 0.1% BASE**	**N18865 001 AUG 31, 1983**
		VALISONE		
AB	+	SCHERING	**EQ 0.1% BASE**	**N16740 001**
	@		EQ 0.1% BASE	N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

		BETOPTIC PILO		
	+	ALCON	EQ 0.25% BASE;1.75%	N20619 001 APR 17, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL

		BETHANECHOL CHLORIDE		
	@	ZENITH GOLDLINE	25MG	N84689 001
AA		ZENITH LABS	**25MG**	**N84689 001**

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

		BLENOXANE		
AP	+	BRISTOL MYERS SQUIBB	**EQ 30 UNITS BASE/VIAL**	**N50443 002 SEP 07, 1995**
		BLEOMYCIN SULFATE		
AP		PHARMACIA AND UPJOHN	**EQ 30 UNITS BASE/VIAL**	**N64084 002 JUN 01, 1996**
	+		EQ 30 UNITS BASE/VIAL	N64084 002 JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	**200MG/100ML**	**N19837 002 APR 12, 1989**
AP	+		**400MG/100ML**	**N19837 001 APR 12, 1989**
	@		200MG/100ML	N19837 002 APR 12, 1989
	@		400MG/100ML	N19837 001 APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

		ALPHAGAN		
	+	ALLERGAN	0.5%	N20490 001 MAR 13, 1997

BROMFENAC SODIUM

CAPSULE; ORAL

		DURACT		
	+	WYETH AYERST	EQ 25MG BASE	N20535 001 JUL 15, 1997

BROMPHENIRAMINE MALEATE

TABLET; ORAL

		BROMPHENIRAMINE MALEATE		
	@	ZENITH GOLDLINE	4MG	N84351 001
	@	ZENITH LABS	4MG	N84351 001

BUDESONIDE

AEROSOL, METERED; NASAL

		RHINOCORT		
	+	ASTRA	0.05MG/INH	N20233 001 FEB 14, 1994
	+		0.032MG/INH	N20233 001 FEB 14, 1994

POWDER, METERED; INHALATION

		PULMICORT		
	+	ASTRA	0.16MG/INH	N20441 002 JUN 24, 1997

BUDESONIDE

POWDER, METERED; INHALATION

	PULMICORT			
	@ ASTRA	0.32MG/INH	N20441 003	JUN 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	ABBOTT	**0.25MG/ML**	**N74160 001**	OCT 30, 1997
AP		**0.25MG/ML**	**N74332 001**	OCT 31, 1994
> ADD > **AP**	GENSIA	**0.25MG/ML**	**N74613 001**	NOV 18, 1997
> ADD > **AP**	SANOFI WINTHROP	**0.25MG/ML**	**N74332 001**	OCT 31, 1994

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPRENORPHINE HCL			
AP	ABBOTT	**EQ 0.3MG BASE/ML**	**N74137 001**	JUN 03, 1996
AP	SANOFI WINTHROP	**EQ 0.3MG BASE/ML**	**N74137 001**	JUN 03, 1996

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN			
+	GLAXO WELLCOME	100MG	N20358 002	OCT 04, 1996
+		150MG	N20358 003	OCT 04, 1996
	ZYBAN			
	GLAXO WELLCOME	100MG	N20711 002	MAY 14, 1997
		150MG	N20711 003	MAY 14, 1997
+		100MG	N20711 002	MAY 14, 1997
+		150MG	N20711 003	MAY 14, 1997

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL			
@ ZENITH GOLDLINE	15MG	N83484 001	
@	30MG	N84040 001	
@ ZENITH LABS	15MG	N83484 001	
@	30MG	N84040 001	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE			
+ SYNTEX	2%	N19881 001	FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	**1MG/ML**	**N74620 001**	JAN 22, 1997
AP		**1MG/ML**	**N74626 001**	JAN 23, 1997
AP		**2MG/ML**	**N74620 002**	JAN 22, 1997
AP		**2MG/ML**	**N74626 002**	JAN 23, 1997
	STADOL			
AP	+ APOTHECON	**2MG/ML**	**N17857 004**	
	STADOL PRESERVATIVE FREE			
AP	+ APOTHECON	**1MG/ML**	**N17857 001**	
AP	+	**2MG/ML**	**N17857 002**	

CALCIPOTRIENE

SOLUTION; TOPICAL

DOVONEX			
+ BRISTOL MYERS SQUIBB	0.005%	N20611 001	MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

	MCGAW	4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML	N19634 002	FEB 24, 1988
@		4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML	N19634 002	FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001	
@		20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001	
@		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001	

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB	+	BRISTOL MYERS SQUIBB	25MG	N18343 002	
AB			25MG	N18343 002	

CAPTOPRIL

AB		EGIS PHARMS	12.5MG	N74748 004	MAY 29, 1997
AB			25MG	N74748 002	MAY 29, 1997
AB			50MG	N74748 001	MAY 29, 1997
AB			100MG	N74748 003	MAY 29, 1997
AB		ENDO LABS	12.5MG	N74418 001	FEB 13, 1996
AB			12.5MG	N74418 001	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	ENDO LABS	25MG	N74418 002	FEB 13, 1996
AB		25MG	N74418 002	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB	PUREPAC PHARM	12.5MG	N74640 001	MAR 31, 1997
AB		25MG	N74640 002	MAR 31, 1997
AB		50MG	N74640 003	MAR 31, 1997
AB		100MG	N74640 004	MAR 31, 1997
AB	STASON	12.5MG	N74677 004	MAY 30, 1997
AB		25MG	N74677 002	MAY 30, 1997
AB		50MG	N74677 001	MAY 30, 1997
AB		100MG	N74677 003	MAY 30, 1997
AB	WOCKHARDT	12.5MG	N74532 001	MAR 28, 1997
AB		25MG	N74532 002	MAR 28, 1997
AB		50MG	N74532 003	MAR 28, 1997
AB		100MG	N74532 004	MAR 28, 1997

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

+	SHIRE LABS	200MG	N20712 001	SEP 30, 1997

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

	CARBATROL			
	+ SHIRE LABS	300MG		N20712 002
				SEP 30, 1997

TABLET; ORAL

	EPITOL			
AB	LEMMON	200MG		N70541 001
				SEP 17, 1986
AB	TEVA	200MG		N70541 001
				SEP 17, 1986

TABLET, CHEWABLE; ORAL

	EPITOL			
AB	LEMMON	100MG		N73524 001
				JUL 29, 1992
AB	TEVA	100MG		N73524 001
				JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	LEMMON	10MG;100MG		N73618 001
				AUG 28, 1992
AB		25MG;100MG		N73589 001
				AUG 28, 1992
AB		25MG;250MG		N73607 001
				AUG 28, 1992
AB	TEVA	10MG;100MG		N73618 001
				AUG 28, 1992
AB		25MG;100MG		N73589 001
				AUG 28, 1992
AB		25MG;250MG		N73607 001
				AUG 28, 1992

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL			
AA	AMIDE PHARM	350MG		N40188 001
				MAR 07, 1997
AA	VINTAGE PHARMS	350MG		N40245 001
				SEP 08, 1997

CARVEDILOL

TABLET; ORAL

	COREG			
	SMITHKLINE BEECHAM	3.125MG		N20297 004
				MAY 29, 1997

CEFACLOR

CAPSULE; ORAL

	CEFACLOR			
AB	RANBAXY	EQ 250MG BASE		N64156 001
				AUG 28, 1997
AB		EQ 500MG BASE		N64156 002
				AUG 28, 1997

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR			
AB	RANBAXY	EQ 125MG BASE/5ML		N64166 001
				OCT 02, 1997
AB		EQ 187MG BASE/5ML		N64165 001
				OCT 02, 1997
AB		EQ 250MG BASE/5ML		N64164 001
				OCT 02, 1997
AB		EQ 375MG BASE/5ML		N64155 001
				OCT 02, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	LEMMON	EQ 250MG BASE/VIAL		N63016 001
				MAR 14, 1989
AP		EQ 500MG BASE/VIAL		N63016 002
				MAR 14, 1989
AP		EQ 1GM BASE/VIAL		N63016 003
				MAR 14, 1989
AP		EQ 5GM BASE/VIAL		N63018 001
				MAR 05, 1990
AP		EQ 10GM BASE/VIAL		N63018 002
				MAR 05, 1990
AP	TEVA	EQ 250MG BASE/VIAL		N63016 001
				MAR 14, 1989
AP		EQ 500MG BASE/VIAL		N63016 002
				MAR 14, 1989
AP		EQ 1GM BASE/VIAL		N63016 003
				MAR 14, 1989

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	TEVA	**EQ 5GM BASE/VIAL**	**N63018 001**	MAR 05, 1990
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	MAR 05, 1990

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

	ROCEPHIN KIT			
+	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006	MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007	MAY 08, 1996

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

	CEFTIN			
+	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
		EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002	APR 29, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME SODIUM			
AB	HANFORD GC	**EQ 750MG BASE/VIAL**	**N64125 001**	MAY 30, 1997
AP		**EQ 1.5GM BASE/VIAL**	**N64125 002**	MAY 30, 1997
AP		**EQ 7.5GM BASE/VIAL**	**N64124 001**	MAY 30, 1997
	KEFUROX			
AB	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**	JAN 10, 1986
AB		**EQ 750MG BASE/VIAL**	**N62592 001**	JAN 10, 1986

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	KEFUROX			
AP	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**	JAN 10, 1986
AP		**EQ 750MG BASE/VIAL**	**N62592 001**	JAN 10, 1986
	ZINACEF			
AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983
AP	+	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	APOTHECON	**EQ 250MG BASE**	**N62973 001**	NOV 08, 1988
AB		**EQ 500MG BASE**	**N62974 001**	NOV 23, 1988
@		EQ 250MG BASE	N62973 001	NOV 08, 1988
@		EQ 500MG BASE	N62974 001	NOV 23, 1988
AB	PUREPAC PHARM	**EQ 250MG BASE**	**N62809 001**	APR 22, 1987
AB		**EQ 500MG BASE**	**N62809 002**	APR 22, 1987
@		EQ 250MG BASE	N62809 001	APR 22, 1987
@		EQ 500MG BASE	N62809 002	APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

	CEFADYL			
	APOTHECON	EQ 1GM BASE/VIAL	N62724 001	DEC 23, 1986
		EQ 2GM BASE/VIAL	N62724 002	DEC 23, 1986
@		EQ 1GM BASE/VIAL	N62724 001	DEC 23, 1986
@		EQ 2GM BASE/VIAL	N62724 002	DEC 23, 1986

CEPHRADINE

CAPSULE; ORAL
CEPHRADINE

	@ ZENITH GOLDLINE	250MG	N62762 001 MAR 06, 1987
	@	500MG	N62762 002 MAR 06, 1987
AB	**ZENITH LABS**	**250MG**	**N62762 001 MAR 06, 1987**
AB		**500MG**	**N62762 002 MAR 06, 1987**

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

	@ BAYER	0.05MG	N20740 001 JUN 26, 1997
	@	0.1MG	N20740 002 JUN 26, 1997
		0.2MG	N20740 003 JUN 26, 1997
	+	0.3MG	N20740 004 JUN 26, 1997

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT

	+ PARKE DAVIS	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002
	@	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE

	PARKE DAVIS	EQ 150MG BASE/5ML	N62301 001
	@	EQ 150MG BASE/5ML	N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

	ROCHE	5MG	N85482 001
		10MG	N85481 001
	+	25MG	N85488 001
	+	5MG	N85482 001
	@	10MG	N85481 001
	@	25MG	N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

	@ ZENITH GOLDLINE	5MG	N83741 001
	@	10MG	N83742 001
	@	25MG	N83570 001
AB	**ZENITH LABS**	**5MG**	**N83741 001**
AB		**10MG**	**N83742 001**
AB		**25MG**	**N83570 001**

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	**LEMMON**	**0.12%**	**N74522 001 DEC 15, 1995**
AT	**TEVA**	**0.12%**	**N74522 001 DEC 15, 1995**

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF

AP	+ ASTRA	**2%**	**N09435 003**
AP	+	**2%**	**N09435 006 MAY 02, 1996**
AP	+	**3%**	**N09435 004**
AP	+	**3%**	**N09435 007 MAY 02, 1996**
	@	2%	N09435 003
	@	3%	N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE		
AA	KV PHARM	**4MG**	**N87164 001**
@		4MG	N87164 001
@	ZENITH GOLDLINE	4MG	N80779 001
@	ZENITH LABS	4MG	N80779 001
	KLOROMIN		
AA	HALSEY	**4MG**	**N83629 001**
@		4MG	N83629 001

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

	CHLORPROMAZINE HCL		
@	ZENITH GOLDLINE	10MG	N83549 001
@		25MG	N83549 002
@		50MG	N83549 003
@		100MG	N83574 001
@		200MG	N83575 001
BP	ZENITH LABS	10MG	N83549 001
BP		25MG	N83549 002
BP		50MG	N83549 003
BP		100MG	N83574 001
BP		200MG	N83575 001

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE		
@	ZENITH GOLDLINE	100MG	N88840 001 OCT 25, 1984
@		250MG	N87353 001
AB	ZENITH LABS	**100MG**	**N88840 001** OCT 25, 1984
AB		**250MG**	**N87353 001**

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE		
@	LEMMON	50MG	N88651 001 MAY 30, 1985
AB	PUREPAC PHARM	**25MG**	**N88139 001** JUL 16, 1986

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE		
AB	PUREPAC PHARM	**50MG**	**N88140 001** AUG 11, 1983
@		25MG	N88139 001 JUL 16, 1986
@		50MG	N88140 001 AUG 11, 1983
@	TEVA	50MG	N88651 001 MAY 30, 1985
AB	ZENITH GOLDLINE	**25MG**	**N88164 001** JAN 09, 1984
AB		**50MG**	**N87176 001**
@		25MG	N87555 001
@		50MG	N87947 001 FEB 27, 1984
AB	ZENITH LABS	**25MG**	**N88164 001** JAN 09, 1984
AB		**50MG**	**N87176 001**
AB		**50MG**	**N87947 001** FEB 27, 1984
@		25MG	N87555 001
	THALITONE		
BX	HORUS THERAP	25MG	N88051 001 NOV 12, 1982
+		15MG	N19574 001 DEC 20, 1988
BX	MONARCH PHARMS	25MG	N19574 002 FEB 12, 1992
+		15MG	N19574 001 DEC 20, 1988
@		25MG	N88051 001 NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE		
AA	LEMMON	**500MG**	**N89859 001** MAY 04, 1988
AA	TEVA	**500MG**	**N89859 001** MAY 04, 1988
	PARAFLEX		
AA	+ JOHNSON RW	**250MG**	**N11300 003**
@		250MG	N11300 003

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997

CICLOPIROX

GEL; TOPICAL
LOPROX

+	HOECHST MARION RSSL	0.77%	N20519 001	JUL 21, 1997

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	ENDO LABS	200MG	N74281 001	MAY 17, 1994
AB		300MG	N74281 002	MAY 17, 1994
AB		400MG	N74281 003	MAY 17, 1994
AB		800MG	N74329 001	MAY 17, 1994
AB	ENDO PHARMS	200MG	N74281 001	MAY 17, 1994
AB		300MG	N74281 002	MAY 17, 1994
AB		400MG	N74281 003	MAY 17, 1994
AB		800MG	N74329 001	MAY 17, 1994
AB	LEMMON	200MG	N74365 001	FEB 28, 1995
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995
AB	SIDMAK LABS NJ	200MG	N74568 001	FEB 27, 1997

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	SIDMAK LABS NJ	300MG	N74568 002	FEB 27, 1997
AB		400MG	N74568 003	FEB 27, 1997
AB		800MG	N74566 001	FEB 27, 1997
AB	TEVA	200MG	N74365 001	FEB 28, 1995
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997
AP	ENDO LABS	EQ 300MG BASE/2ML	N74005 001	AUG 31, 1994
AP	ENDO PHARMS	EQ 300MG BASE/2ML	N74005 001	AUG 31, 1994
AP	GENSIA	EQ 300MG BASE/2ML	N74252 001	NOV 26, 1997
AP	SANOFI	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997

SOLUTION; ORAL
CIMETIDINE HCL

AA	ENDO LABS	EQ 300MG BASE/5ML	N74251 001	DEC 22, 1994
AA	ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001	DEC 22, 1994
AA	HI TECH PHARMA	EQ 300MG BASE/5ML	N74664 001	OCT 28, 1997
AA	MORTON GROVE	EQ 300MG BASE/5ML	N74757 001	OCT 17, 1997

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001	JAN 27, 1997
AA	ROXANE	EQ 300MG BASE/5ML	N74541 001	AUG 05, 1997

CIPROFLOXACIN

POWDER FOR RECONSTITUTION; ORAL

	CIPRO			
	BAYER	250MG/5ML	N20780 001	SEP 26, 1997
+		500MG/5ML	N20780 002	SEP 26, 1997

CISAPRIDE MONOHYDRATE

TABLET; ORAL

> ADD >		PROPULSID QUICKSOLV			
> ADD >	+	JANSSEN	EQ 20MG BASE	N20767 001	NOV 07, 1997
> ADD >					

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994
AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994

TABLET; ORAL

	CLEMASTINE FUMARATE			
AB	LEMMON	2.68MG	N73283 001	JAN 31, 1992
	@	1.34MG	N73282 001	JAN 31, 1992
AB	TEVA	2.68MG	N73283 001	JAN 31, 1992
	@	1.34MG	N73282 001	JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	QUAD PHARMS	EQ 150MG BASE/ML	N62795 001	DEC 21, 1987
	@	EQ 150MG BASE/ML	N62795 001	DEC 21, 1987

SOLUTION; TOPICAL

	CLINDAMYCIN PHOSPHATE			
AT	FOUGERA	EQ 1% BASE	N64159 001	JUN 05, 1997
AT	LEMMON	EQ 1% BASE	N62930 001	JUN 28, 1989
AT	MORTON GROVE	EQ 1% BASE	N63304 001	JUL 15, 1997
AT	TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CORMAX			
AB	HEALTHPOINT	0.05%	N74220 001	MAY 16, 1997

GEL; TOPICAL

	CLOBETASOL PROPIONATE			
AB	STIEFEL	0.05%	N75027 001	OCT 31, 1997
	TEMOVATE			
AB	+ GLAXO WELLCOME	0.05%	N20337 001	APR 29, 1994

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

	CLODERM			
+	CTR LABS	0.1%	N17765 001	
+	EM INDS	0.1%	N17765 001	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	INVAMED	25MG	N74953 001 JUN 25, 1997	
AB		50MG	N74953 002 JUN 25, 1997	
AB		75MG	N74953 003 JUN 25, 1997	> ADD >
AB	LEMMON	25MG	N74958 001 AUG 26, 1997	> ADD >
AB		50MG	N74958 002 AUG 26, 1997	> ADD >
AB		75MG	N74958 003 AUG 26, 1997	> ADD >
AB	NOVOPHARM	25MG	N74849 001 APR 04, 1997	
AB		50MG	N74849 002 APR 04, 1997	
AB		75MG	N74849 003 APR 04, 1997	

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB	ALPHAPHARM	0.5MG	N74940 001 OCT 30, 1997
AB		1MG	N74940 002 OCT 30, 1997
AB		2MG	N74940 003 OCT 30, 1997
AB	EON	0.5MG	N74979 001 AUG 29, 1997
AB		1MG	N74979 002 AUG 29, 1997
AB		2MG	N74979 003 AUG 29, 1997
AB	INVAMED	0.5MG	N74925 001 SEP 30, 1997
AB		1MG	N74925 002 SEP 30, 1997
AB		2MG	N74925 003 SEP 30, 1997

KLONOPIN

+	ROCHE	0.125MG	N17533 005 APR 09, 1997

CLONAZEPAM

TABLET; ORAL
KLONOPIN

	ROCHE	0.25MG	N17533 006 APR 09, 1997

CLOPIDOGREL BISULFATE

TABLET; ORAL
PLAVIX

+	SANOFI	EQ 75MG BASE	N20839 001 NOV 17, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	PUREPAC PHARM	7.5MG	N71925 001 APR 25, 1988
AB		15MG	N71926 001 APR 25, 1988
	@	7.5MG	N71925 001 APR 25, 1988
	@	15MG	N71926 001 APR 25, 1988

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	PUREPAC PHARM	3.75MG	N72330 001 AUG 08, 1988
AB		7.5MG	N72331 001 AUG 08, 1988
AB		15MG	N72332 001 AUG 08, 1988
	@	3.75MG	N72330 001 AUG 08, 1988
	@	7.5MG	N72331 001 AUG 08, 1988
	@	15MG	N72332 001 AUG 08, 1988

CLOZAPINE

TABLET; ORAL

		CLOZAPINE		
> ADD >	**AB**	ZENITH GOLDLINE	**25MG**	**N74949 001**
> ADD >				NOV 26, 1997
> ADD >	**AB**		**100MG**	**N74949 002**
> ADD >				NOV 26, 1997

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHERAZINE W/ CODEINE		
AA	HALSEY	**10MG/5ML;6.25MG/5ML**	**N88739 001**
			DEC 23, 1988
	@	10MG/5ML;6.25MG/5ML	N88739 001
			DEC 23, 1988
	PROMETHAZINE HCL AND CODEINE PHOSPHATE		
AA	HI TECH PHARMA	**10MG/5ML;6.25MG/5ML**	**N40151 001**
			AUG 26, 1997

CORTICOTROPIN

INJECTABLE; INJECTION

	ACTHAR		
AP	+ RHONE POULENC RORER	**40 UNITS/VIAL**	**N07504 003**
	+	25 UNITS/VIAL	N07504 002
	@	25 UNITS/VIAL	N07504 002
	@	40 UNITS/VIAL	N07504 003
	CORTICOTROPIN		
AP	STERIS	**40 UNITS/VIAL**	**N88772 001**
			NOV 21, 1984
	+	40 UNITS/VIAL	N88772 001
			NOV 21, 1984

CORTISONE ACETATE

TABLET; ORAL

	CORTISONE ACETATE		
BP	PUREPAC PHARM	25MG	**N80493 001**
	@	25MG	N80493 001
	@ ZENITH GOLDLINE	25MG	N80630 001
	@	25MG	N83536 001
	@ ZENITH LABS	25MG	**N80630 001**
	@	25MG	**N83536 001**

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

	INTAL		
	+ FISONS	0.8MG/INH	**N18887 001**
			DEC 05, 1985
	+ RHONE POULENC RORER	0.8MG/INH	N18887 001
			DEC 05, 1985

CAPSULE; INHALATION

	INTAL		
	+ FISONS	20MG	**N16990 001**
	+ RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION

	INTAL		
AN	+ FISONS	**10MG/ML**	**N18596 001**
			MAY 28, 1982
AN	+ RHONE POULENC RORER	**10MG/ML**	**N18596 001**
			MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC

	OPTICROM		
	@ FISONS	4%	**N18155 001**
			OCT 03, 1984
	@ RHONE POULENC RORER	4%	N18155 001
			OCT 03, 1984

SPRAY, METERED; NASAL

	NASALCROM		
	+ FISONS	5.2MG/SPRAY	**N18306 001**
			MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION

	COBAVITE		
AP	STERIS	**0.1MG/ML**	**N83013 001**
AP		**1MG/ML**	**N83064 001**
	@	0.1MG/ML	N83013 001
	@	1MG/ML	N83064 001
	CYANOCOBALAMIN		
AP	STERIS	**0.1MG/ML**	**N83120 001**
	@	0.1MG/ML	N83120 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

		DICOPAC KIT		
>_DLT_>		MEDI PHYSICS	N/A;N/A;N/A	N17406 001
>_ADD_>		NYCOMED AMERSHAM	N/A;N/A;N/A	N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		AK-PENTOLATE		
AT		AKORN	**1%**	**N85555 001**
	@		1%	N85555 001
		AKPENTOLATE		
AT		AKORN	**1%**	**N40164 001** JAN 13, 1997
AT			**2%**	**N40165 001** JAN 13, 1997
		CYCLOGYL		
AT	+	ALCON	**2%**	**N84108 001**

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

		CYCLOPHOSPHAMIDE		
AP		ASTA	**100MG/VIAL**	**N88371 001** JUL 03, 1986
AP			**200MG/VIAL**	**N88372 001** JUL 03, 1986
AP			**500MG/VIAL**	**N88373 001** JUL 03, 1986
AP			**1GM/VIAL**	**N88374 001** SEP 24, 1986
AP		ELKINS SINN	**100MG/VIAL**	**N88371 001** JUL 03, 1986
AP			**200MG/VIAL**	**N88372 001** JUL 03, 1986
AP			**500MG/VIAL**	**N88373 001** JUL 03, 1986
AP			**1GM/VIAL**	**N88374 001** SEP 24, 1986
		CYTOXAN		
AP	+	BRISTOL MYERS SQUIBB	**100MG/VIAL**	**N12142 001**
AP	+		**200MG/VIAL**	**N12142 002**
AP	+		**500MG/VIAL**	**N12142 003**
AP	+		**1GM/VIAL**	**N12142 004** AUG 30, 1982

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

		CYTOXAN		
AP	+	BRISTOL MYERS SQUIBB	**2GM/VIAL**	**N12142 005** AUG 30, 1982
	@		100MG/VIAL	N12142 001
	@		200MG/VIAL	N12142 002
	@		500MG/VIAL	N12142 003
	@		1GM/VIAL	N12142 004 AUG 30, 1982
	@		2GM/VIAL	N12142 005 AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL		
AA		HALSEY	**4MG**	**N89057 001** JUL 03, 1986
	@		4MG	N89057 001 JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		CERUBIDINE		
AP		RHONE POULENC RORER	**EQ 20MG BASE/VIAL**	**N61876 001**
	@		EQ 20MG BASE/VIAL	N61876 001
AP	+	WYETH AYERST	**EQ 20MG BASE/VIAL**	**N50484 001**
	@		EQ 20MG BASE/VIAL	N50484 001
		DAUNORUBICIN HCL		
AP		BEDFORD	**EQ 20MG BASE/VIAL**	**N64103 001** FEB 03, 1995
	+		EQ 20MG BASE/VIAL	N64103 001 FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL

		RESCRIPTOR		
	+	PHARMACIA AND UPJOHN	100MG	N20705 001 APR 04, 1997

DESERPIDINE

TABLET; ORAL
HARMONYL
+ ABBOTT 0.25MG N10796 002
@ 0.25MG N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB SIDMAK LABS NJ 100MG N71803 001 MAY 29, 1997
AB 150MG N71804 001 MAY 29, 1997

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP
AP + RHONE POULENC RORER 0.004MG/ML N18938 001 MAR 30, 1984

DESMOPRESSIN ACETATE
AP GENSIA 0.004MG/ML N74888 001 OCT 15, 1997

SPRAY, METERED; NASAL
DDAVP
+ RHONE POULENC RORER 0.01MG/SPRAY N17922 002 FEB 06, 1989
@ 0.01MG/SPRAY N17922 002 FEB 06, 1989
+ 0.01MG/SPRAY N17922 003 AUG 07, 1996

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
AA ALPHARMA 0.5MG/5ML N88997 001 OCT 10, 1986
@ 0.5MG/5ML N88997 001 OCT 10, 1986

GEL; TOPICAL
DECADERM
+ MERCK SHARP DOHME 0.1% N13538 001

DEXAMETHASONE

GEL; TOPICAL
DECADERM
@ MERCK SHARP DOHME 0.1% N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN
AT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N64063 001 JUL 25, 1994

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
AT BAUSCH AND LOMB 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N64063 001 JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL
DECADRON
+ MERCK SHARP DOHME EQ 0.1% PHOSPHATE N11983 002
@ EQ 0.1% PHOSPHATE N11983 002

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS EQ 4MG PHOSPHATE/ML N84355 001
@ EQ 4MG PHOSPHATE/ML N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;37MG/100ML N19699 001 SEP 29, 1989
@ 5GM/100ML;37MG/100ML N19699 001 SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 5GM/100ML;75MG/100ML N19699 002 SEP 29, 1989
@ 5GM/100ML;75MG/100ML N19699 002 SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;110MG/100ML	N19699 003 SEP 29, 1989
@		5GM/100ML;110MG/100ML	N19699 003 SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;220MG/100ML	N19699 005 SEP 29, 1989
@		5GM/100ML;220MG/100ML	N19699 005 SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

AP	MCGAW	**5GM/100ML;75MG/100ML; 200MG/100ML**	**N18268 009**
@		5GM/100ML;75MG/100ML; 200MG/100ML	N18268 009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;150MG/100ML; 200MG/100ML**	**N18268 004**
@		5GM/100ML;150MG/100ML; 200MG/100ML	N18268 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;220MG/100ML; 200MG/100ML**	**N18268 005**
@		5GM/100ML;220MG/100ML; 200MG/100ML	N18268 005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;300MG/100ML; 200MG/100ML**	**N18268 006**
@		5GM/100ML;300MG/100ML; 200MG/100ML	N18268 006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;75MG/100ML; 330MG/100ML**	**N18268 011 JAN 18, 1986**

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

@	MCGAW	5GM/100ML;75MG/100ML; 330MG/100ML	N18268 011 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;150MG/100ML; 330MG/100ML**	**N18268 012 JAN 18, 1986**
@		5GM/100ML;150MG/100ML; 330MG/100ML	N18268 012 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;220MG/100ML; 330MG/100ML**	**N18268 013 JAN 18, 1986**
@		5GM/100ML;220MG/100ML; 330MG/100ML	N18268 013 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;300MG/100ML; 330MG/100ML**	**N18268 014 JAN 18, 1986**
@		5GM/100ML;300MG/100ML; 330MG/100ML	N18268 014 JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

AP	MCGAW	**5GM/100ML;75MG/100ML; 450MG/100ML**	**N18268 010**
@		5GM/100ML;75MG/100ML; 450MG/100ML	N18268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	MCGAW	**5GM/100ML;150MG/100ML; 450MG/100ML**	**N18268 001**
@		5GM/100ML;150MG/100ML; 450MG/100ML	N18268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

@	MCGAW	5GM/100ML;220MG/100ML; 450MG/100ML	N18268 002	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	**MCGAW**	**5GM/100ML;300MG/100ML; 450MG/100ML**	**N18268 003**	
@		5GM/100ML;300MG/100ML; 450MG/100ML	N18268 003	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**MCGAW**	**10GM/100ML;900MG/100ML**	**N18047 001**	
@		10GM/100ML;900MG/100ML	N18047 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**MCGAW**	**5GM/100ML;900MG/100ML**	**N18026 001**	
@		5GM/100ML;900MG/100ML	N18026 001	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

	KNOLL PHARM	1MG	N12302 005	
		2MG	N12302 002	
+		4MG	N12302 004	
@		1MG	N12302 005	
@		2MG	N12302 002	
@		4MG	N12302 004	

DIAZEPAM

GEL; RECTAL

DIASTAT

+	ATHENA	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997

DIAZEPAM

GEL; RECTAL

DIASTAT

	ATHENA	15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP	ABBOTT	**5MG/ML**	**N72079 001**	DEC 20, 1988
AP	STERIS	**5MG/ML**	**N70912 001**	AUG 28, 1986
@		5MG/ML	N70912 001	AUG 28, 1986
AP	STERLING WINTHROP	**5MG/ML**	**N72079 001**	DEC 20, 1988

TABLET; ORAL

DIAZEPAM

AB	HALSEY	**2MG**	**N70987 001**	AUG 15, 1986
AB		**5MG**	**N70996 001**	AUG 15, 1986
AB		**10MG**	**N70956 001**	AUG 15, 1986
@		2MG	N70987 001	AUG 15, 1986
@		5MG	N70996 001	AUG 15, 1986
@		10MG	N70956 001	AUG 15, 1986
AB	ZENITH GOLDLINE	**10MG**	**N70362 001**	SEP 04, 1985
@		2MG	N70360 001	SEP 04, 1985
@		5MG	N70361 001	SEP 04, 1985
@		10MG	N70362 001	SEP 04, 1985
@	ZENITH LABS	2MG	N70360 001	SEP 04, 1985
@		5MG	N70361 001	SEP 04, 1985

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM			
AB	COPLEY PHARM	25MG	N74459 001	JUN 25, 1997
AB		50MG	N74459 002	JUN 25, 1997
AB		75MG	N74459 003	JUN 25, 1997

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL			
AB	WEST WARD	10MG	N40204 001	FEB 28, 1997

SYRUP; ORAL

	BENTYL			
AA	+ HOECHST MARION RSSL	10MG/5ML	N07961 002	OCT 15, 1984
	+	10MG/5ML	N07961 002	OCT 15, 1984
	DICYCLOMINE HCL			
AA	ALPHARMA	10MG/5ML	N84479 001	
	@	10MG/5ML	N84479 001	

DIETHYLSTILBESTROL

TABLET; ORAL

	DIETHYLSTILBESTROL			
	LILLY	1MG	N04041 004	
	+	5MG	N04041 005	
	@	1MG	N04041 004	
	@	5MG	N04041 005	
	STILBESTROL			
	TABLICAPS	0.5MG	N83004 001	
	@	0.5MG	N83004 001	
	STILBESTROL TAB			
	SMITH MILLER PATCH	25MG	N06194 001	

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL			
AB	DANBURY PHARMA	250MG	N74400 001	JUL 17, 1997
AB		500MG	N74400 002	JUL 17, 1997

DIGOXIN

INJECTABLE; INJECTION

	DIGOXIN			
AP	ABBOTT	0.25MG/ML	N40093 001	MAY 16, 1996
AP	SANOFI WINTHROP	0.25MG/ML	N40093 001	MAY 16, 1996
	DIGOXIN PEDIATRIC			
AP	ABBOTT	0.1MG/ML	N40092 001	APR 25, 1996
AP	SANOFI WINTHROP	0.1MG/ML	N40092 001	APR 25, 1996

TABLET; ORAL

	LANOXIN			
	@ GLAXO WELLCOME	0.0625MG	N20405 001	SEP 30, 1997
		0.125MG	N20405 002	SEP 30, 1997
	@	0.1875MG	N20405 003	SEP 30, 1997
	+	0.25MG	N20405 004	SEP 30, 1997
	@	0.375MG	N20405 005	SEP 30, 1997
	@	0.5MG	N20405 006	SEP 30, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM SR			
AB	+ HOECHST MARION RSSL	60MG	N19471 001	JAN 23, 1989
AB1	+	60MG	N19471 001	JAN 23, 1989

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		CARDIZEM SR			
AB	+	HOECHST MARION RSSL	**90MG**	**N19471 002**	**JAN 23, 1989**
AB1	+		**90MG**	**N19471 002**	JAN 23, 1989
AB	+		**120MG**	**N19471 003**	**JAN 23, 1989**
AB1	+		**120MG**	**N19471 003**	JAN 23, 1989
		DILACOR XR			
AB2	+	WATSON LABS	**120MG**	**N20092 001**	MAY 29, 1992
AB2	+		**180MG**	**N20092 002**	MAY 29, 1992
AB2	+		**240MG**	**N20092 003**	MAY 29, 1992
		DILTIAZEM HCL			
AB2		ANDRX	**120MG**	**N74852 001**	OCT 10, 1997
AB2			**180MG**	**N74852 002**	OCT 10, 1997
AB2			**240MG**	**N74852 003**	OCT 10, 1997
AB		MYLAN	**60MG**	**N74910 001**	**MAY 02, 1997**
AB1			**60MG**	**N74910 001**	MAY 02, 1997
AB			**90MG**	**N74910 002**	**MAY 02, 1997**
AB1			**90MG**	**N74910 002**	MAY 02, 1997
AB			**120MG**	**N74910 003**	**MAY 02, 1997**
AB1			**120MG**	**N74910 003**	MAY 02, 1997
AB		PROGRAPHARM	**60MG**	**N74079 001**	NOV 30, 1993
AB			**90MG**	**N74079 002**	NOV 30, 1993
AB			**120MG**	**N74079 003**	NOV 30, 1993
AB1		TEVA	**60MG**	**N74079 001**	NOV 30, 1993
AB1			**90MG**	**N74079 002**	NOV 30, 1993

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		DILTIAZEM HCL			
AB1		TEVA	**120MG**	**N74079 003**	NOV 30, 1993

INJECTABLE; INJECTION

		CARDIZEM			
AP	+	HOECHST MARION RSSL	**100MG/VIAL**	**N20792 001**	SEP 05, 1997
		DILTIAZEM HCL			
AP		GENSIA	**5MG/ML**	**N74894 001**	AUG 26, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION

		DIMENHYDRINATE			
AP		ELKINS SINN	**50MG/ML**	**N84767 001**	
	@		50MG/ML	N84767 001	

DIMERCAPROL

INJECTABLE; INJECTION

		BAL			
	+	AKORN	10%	N05939 001	
	+	BECTON DICKINSON	10%	N05939 001	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		DIPHENHYDRAMINE HCL			
AA		ECN	**25MG**	**N80845 002**	
AA			**50MG**	**N80845 001**	
	@		25MG	N80845 002	
	@		50MG	N80845 001	
	@	ZENITH GOLDLINE	25MG	N80762 001	
	@		50MG	N80762 002	
AA		ZENITH LABS	**25MG**	**N80762 001**	
AA			**50MG**	**N80762 002**	

INJECTABLE; INJECTION

		BENADRYL			
AP	+	PARKE DAVIS	**10MG/ML**	**N06146 001**	
AP	+		**50MG/ML**	**N09486 001**	

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BENADRYL			
	@ PARKE DAVIS	10MG/ML		N06146 001
	BENADRYL PRESERVATIVE FREE			
AP	+ PARKE DAVIS	50MG/ML		N09486 001
	DIPHENHYDRAMINE HCL			
AP	FUJISAWA	50MG/ML		N80586 002
AP	INTL MEDICATION	50MG/ML		N84094 001
AP	STERIS	10MG/ML		N80873 001
AP		10MG/ML		N83533 001
	+	10MG/ML		N80873 001
	@	10MG/ML		N83533 001
	DIPHENHYDRAMINE HCL PRESERVATIVE FREE			
AP	FUJISAWA	50MG/ML		N80586 002
AP	INTL MEDICATION	50MG/ML		N84094 001
AP	STERIS	50MG/ML		N80873 003

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE			
> ADD > AP	GENSIA	5MG/ML		N74952 001
> ADD >				NOV 26, 1997

TABLET; ORAL

	DIPYRIDAMOLE			
AB	CHELSEA LABS	50MG		N87160 001
				JUN 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC			
	@ LILLY	250MG		N50678 001
				JUN 19, 1995
	+	250MG		N50678 001
				JUN 19, 1995

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL			
AP	ABBOTT	EQ 12.5MG BASE/ML		N74292 001
				FEB 16, 1995

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL			
AP	SANOFI WINTHROP	EQ 12.5MG BASE/ML		N74292 001
				FEB 16, 1995

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

	ANZEMET			
	+ HOECHST MARION RSSL	EQ 20MG BASE/ML		N20624 001
				SEP 11, 1997

TABLET; ORAL

	ANZEMET			
	HOECHST MARION RSSL	EQ 50MG BASE		N20623 001
				SEP 11, 1997
	+	EQ 100MG BASE		N20623 002
				SEP 11, 1997

DOXAZOSIN MESYLATE

TABLET; ORAL

	CARDURA			
	PFIZER	EQ 1MG BASE		N19668 001
				NOV 02, 1990
	+	EQ 8MG BASE		N19668 004
				NOV 02, 1990
	+	EQ 1MG BASE		N19668 001
				NOV 02, 1990
		EQ 8MG BASE		N19668 004
				NOV 02, 1990

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	DOXEPIN HCL			
AB	PUREPAC PHARM	EQ 100MG BASE		N72110 001
				SEP 08, 1988
	@	EQ 100MG BASE		N72110 001
				SEP 08, 1988

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX

AB	PARKE DAVIS	EQ 100MG BASE	N62653 001	OCT 30, 1985
AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001	OCT 30, 1985

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	ABBOTT	2.5MG/ML	N72272 001	AUG 31, 1995
AP	SANOFI WINTHROP	2.5MG/ML	N72272 001	AUG 31, 1995

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

+	J AND J	1%	N18751 001	DEC 23, 1982
+	JOHNSON RW	1%	N18751 001	DEC 23, 1982

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ALPHACAINE HCL W/ EPINEPHRINE

> DLT >				
> DLT >	AP	CARLISLE	0.01MG/ML;2%	N84720 001
> DLT >	AP		0.02MG/ML;2%	N84732 001
> ADD >	@		0.01MG/ML;2%	N84720 001
> ADD >	@		0.02MG/ML;2%	N84732 001

ERGOLOID MESYLATES

TABLET; SUBLINGUAL
HYDROGENATED ERGOT ALKALOIDS

@	ZENITH GOLDLINE	0.5MG	N87186 001
@	ZENITH LABS	0.5MG	N87186 001

ERYTHROMYCIN

GEL; TOPICAL
ERYTHROMYCIN

AT	ALTANA	2%	N64184 001	SEP 30, 1997

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	ALTANA	2%	N64187 001	SEP 30, 1997
AT	STIEFEL	2%	N64127 001	FEB 14, 1997

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE

@	ZENITH GOLDLINE	EQ 250MG BASE	N62237 001	
AB	ZENITH LABS	EQ 250MG BASE	N62237 001	

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB	ROYCE LABS	1MG	N74818 001	AUG 19, 1997
AB		2MG	N74818 002	AUG 19, 1997
AB	TEVA	1MG	N74921 001	JUL 10, 1997
AB		2MG	N74921 002	JUL 10, 1997
AB	ZENITH GOLDLINE	1MG	N74826 001	JUL 03, 1997
AB		2MG	N74826 002	JUL 03, 1997

PROSOM

AB	ABBOTT	1MG	N19080 001	DEC 26, 1990
AB +		2MG	N19080 002	DEC 26, 1990

ESTRADIOL

TABLET; ORAL
ESTRADIOL

AB	BARR	0.5MG	N40197 001 OCT 22, 1997
AB		1MG	N40197 002 OCT 22, 1997
AB		2MG	N40197 003 OCT 22, 1997

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
ALESSE

+	WYETH AYERST	0.02MG;0.1MG	N20683 001 MAR 27, 1997

TABLET; ORAL-28
ALESSE

	WYETH AYERST	0.02MG;0.1MG	N20683 002 MAR 27, 1997

ETODOLAC

> ADD >
> ADD >

CAPSULE; ORAL
ETODOLAC

AB	ENDO PHARMS	200MG	N74842 001 JUL 17, 1997
AB		300MG	N74842 002 JUL 17, 1997
AB	GENEVA PHARMS	200MG	N74840 001 AUG 29, 1997
AB		300MG	N74840 002 AUG 29, 1997
AB	INVAMED	200MG	N74942 001 SEP 30, 1997
AB		300MG	N74942 002 SEP 30, 1997
AB	MYLAN	200MG	N74932 001 MAY 16, 1997
AB		300MG	N74932 002 MAY 16, 1997
AB	ZENITH GOLDLINE	200MG	N74899 001 JUL 08, 1997
AB		300MG	N74899 002 JUL 08, 1997

ETODOLAC

CAPSULE; ORAL
LODINE

AB	WYETH AYERST	200MG	N18922 002 JAN 31, 1991
AB	+	300MG	N18922 003 JAN 31, 1991

TABLET; ORAL
ETODOLAC

AB	AESGEN	400MG	N74927 001 OCT 30, 1997
AB	ENDO PHARMS	400MG	N74841 001 JUN 27, 1997
AB	EON	400MG	N74903 001 APR 11, 1997
AB	GENEVA PHARMS	400MG	N74839 001 JUL 11, 1997
AB	INVAMED	400MG	N74846 001 FEB 28, 1997
AB	PUREPAC PHARM	400MG	N74819 001 FEB 28, 1997
AB	ROYCE LABS	400MG	N74892 001 APR 16, 1997
AB	TEVA	400MG	N75009 001 NOV 26, 1997
AB	ZENITH GOLDLINE	400MG	N74883 001 FEB 28, 1997

LODINE

AB	WYETH AYERST	400MG	N18922 004 JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	IMMUNEX	20MG/ML	N74513 001 MAR 14, 1996
AP	PIERRE FABRE	20MG/ML	N74813 001 JUL 09, 1997
AP	SUPERGEN	20MG/ML	N74513 001 MAR 14, 1996

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IN PLASTIC CONTAINER
> DLT >
> DLT > + MERCK 0.4MG/ML N20249 001
> DLT > FEB 18, 1994
> ADD >
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
> ADD > + MERCK 0.4MG/ML N20249 001
> ADD > FEB 18, 1994

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM
+ NEUREX EQ 10MG BASE/ML N19922 001
SEP 23, 1997

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
AP ABBOTT **EQ 0.05MG BASE/ML** **N72786 001**
SEP 24, 1991
AP STERLING WINTHROP **EQ 0.05MG BASE/ML** **N72786 001**
SEP 24, 1991

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
@ 3M 50MG N18830 004
AUG 23, 1988
@ 100MG N18830 001
OCT 31, 1985
@ 150MG N18830 003
JUN 03, 1988
50MG N18830 004
AUG 23, 1988
100MG N18830 001
OCT 31, 1985
+ 150MG N18830 003
JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN
+ PFIZER 200MG/100ML N19950 001
JAN 29, 1990
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 003
SEP 29, 1992
@ 2MG/ML N19950 005
JUL 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9%
+ PFIZER 200MG/100ML N19950 001
JAN 29, 1990
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 002
JAN 29, 1990
@ 2MG/ML N19950 004
JUL 08, 1994

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON
ICN 250MG N17001 001
+ 500MG N17001 002
ROCHE 250MG N17001 001
+ 500MG N17001 002

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE
BX + DURA 0.025MG/SPRAY N18148 001
BX + SYNTEX 0.025MG/SPRAY N18148 001
NASAREL
BX + DURA 0.025MG/SPRAY N20409 001
MAR 08, 1995
BX + SYNTEX 0.025MG/SPRAY N20409 001
MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCET
@ ALPHARMA 0.025% N88360 001
JAN 16, 1984

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCET			
AT	NMC	0.025%	N88360 001	
			JAN 16, 1984	
	FLUOCINOLONE ACETONIDE			
	@ ALPHARMA	0.01%	N88361 001	
			JAN 16, 1984	
AT	NMC	0.01%	N88361 001	
			JAN 16, 1984	
	SYNALAR			
AT	+ MEDICIS	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
AT	+ SYNTEX	0.01%	N12787 004	
AT	+	0.025%	N12787 002	
AT	+	0.025%	N12787 005	
	SYNALAR-HP			
	+ MEDICIS	0.2%	N16161 002	
	+ SYNTEX	0.2%	N16161 002	

OINTMENT; TOPICAL

	SYNALAR			
AT	+ MEDICIS	0.025%	N13960 001	
AT	+ SYNTEX	0.025%	N13960 001	

SOLUTION; TOPICAL

	SYNALAR			
AT	+ MEDICIS	0.01%	N15296 001	
AT	+ SYNTEX	0.01%	N15296 001	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

	NEO-SYNALAR			
	+ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	
	+ SYNTEX	0.025%;EQ 3.5MG BASE/GM	N60700 001	

FLUOCINONIDE

CREAM; TOPICAL

	LIDEX			
AB	+ MEDICIS	0.05%	N16908 002	
AB	+ SYNTEX	0.05%	N16908 002	
	LIDEX-E			
AB	MEDICIS	0.05%	N16908 003	

FLUOCINONIDE

CREAM; TOPICAL

	LIDEX-E			
AB	SYNTEX	0.05%	N16908 003	

GEL; TOPICAL

	FLUOCINONIDE			
AB	TARO	0.05%	N74935 001	
			JUL 29, 1997	
	LIDEX			
AB	+ MEDICIS	0.05%	N17373 001	
AB	+ SYNTEX	0.05%	N17373 001	

OINTMENT; TOPICAL

	FLUOCINONIDE			
AB	ALTANA	0.05%	N74905 001	
			AUG 26, 1997	
	LIDEX			
AB	+ MEDICIS	0.05%	N16909 002	
AB	+ SYNTEX	0.05%	N16909 002	

SOLUTION; TOPICAL

	LIDEX			
AT	+ MEDICIS	0.05%	N18849 001	
			APR 06, 1984	
AT	+ SYNTEX	0.05%	N18849 001	
			APR 06, 1984	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP			
	+ LILLY	0.025%	N12806 003	
	+	0.05%	N12806 002	
	+ OCLASSEN	0.025%	N12806 003	
	+	0.05%	N12806 002	

LOTION; TOPICAL

	CORDRAN			
AT	+ LILLY	0.05%	N13790 001	
AT	+ OCLASSEN	0.05%	N13790 001	

OINTMENT; TOPICAL

	CORDRAN			
	+ LILLY	0.025%	N12806 004	
	+	0.05%	N12806 001	
	+ OCLASSEN	0.025%	N12806 004	

FLURANDRENOLIDE

OINTMENT; TOPICAL
CORDRAN
+ OCLASSEN 0.05% N12806 001

TAPE; TOPICAL
CORDRAN
+ LILLY 0.004MG/SQ CM N16455 001
+ OCLASSEN 0.004MG/SQ CM N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL
AB HALSEY 15MG N71808 001 JAN 07, 1988
AB 30MG N71809 001 JAN 07, 1988
@ 15MG N71808 001 JAN 07, 1988
@ 30MG N71809 001 JAN 07, 1988

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
AB SIDMAK LABS NJ 50MG N74647 001 APR 01, 1997
AB 100MG N74647 002 APR 01, 1997
AB WARNER CHILCOTT 100MG N74560 002 MAY 16, 1997

FLUTICASONE PROPIONATE

>ADD> POWDER; INHALATION
>ADD> FLOVENT
>ADD> + GLAXO WELLCOME 0.044MG/INH N20549 001 NOV 07, 1997
>ADD> + 0.088MG/INH N20549 002 NOV 07, 1997
>ADD> + 0.22MG/INH N20549 003 NOV 07, 1997

FOLIC ACID

TABLET; ORAL
FOLIC ACID
AA DANBURY PHARMA 1MG N80680 001
AA + 1MG N80680 001
FOLVITE
AA + LEDERLE 1MG N05897 004
@ 1MG N05897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION
FOLLISTIM
BX ORGANON 75 IU/VIAL N20582 001 SEP 29, 1997
BX 150 IU/VIAL N20582 002 SEP 29, 1997
GONAL-F
BX SERONO 75 IU/VIAL N20378 001 SEP 29, 1997
BX 150 IU/VIAL N20378 002 SEP 29, 1997

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP ABBOTT 10MG/ML N70578 001 JUL 08, 1987
AP 10MG/ML N72080 001 AUG 13, 1991
AP 10MG/ML N74337 001 OCT 31, 1994
AP SANOFI WINTHROP 10MG/ML N74337 001 OCT 31, 1994
AP STERLING WINTHROP 10MG/ML N70578 001 JUL 08, 1987
AP 10MG/ML N72080 001 AUG 13, 1991

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
NEOSCAN
>DLT> BS MEDI PHYSICS 2mCi/ML N17655 001

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
NEOSCAN

> ADD	BS	NYCOMED AMERSHAM	2mCi/ML	N17655 001	

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

	@ ALPHARMA	EQ 0.1% BASE	N62471 001 SEP 27, 1983	> ADD >
AT	NMC	**EQ 0.1% BASE**	**N62471 001** **SEP 27, 1983**	> ADD > > ADD > > ADD >

OINTMENT; TOPICAL
GENTAMICIN SULFATE

	@ ALPHARMA	EQ 0.1% BASE	N62496 001 MAR 14, 1984
AT	NMC	**EQ 0.1% BASE**	**N62496 001** **MAR 14, 1984**

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	DURAMED	**5MG**	**N74550 001** SEP 11, 1997
AB		**10MG**	**N74550 002** SEP 11, 1997
AB	ENDO LABS	**5MG**	**N74378 001** NOV 28, 1994
AB		**10MG**	**N74378 002** NOV 28, 1994
AB	ENDO PHARMS	**5MG**	**N74378 001** NOV 28, 1994
AB		**10MG**	**N74378 002** NOV 28, 1994
AB	SIDMAK LABS NJ	**5MG**	**N74619 001** APR 04, 1997
AB		**10MG**	**N74619 002** APR 04, 1997

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

AA	HALSEY	**500MG**	**N89459 001** OCT 10, 1986
	@	500MG	N89459 001 OCT 10, 1986

> ADD >

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

+	GLAXO WELLCOME	EQ 200MG BASE	N20695 001 NOV 06, 1997

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V

+	J AND J	125MG/5ML	N50448 001
		125MG/5ML	N62483 001 JAN 26, 1984
+	JOHNSON RW	125MG/5ML	N50448 001
		125MG/5ML	N62483 001 JAN 26, 1984

TABLET; ORAL
GRIFULVIN V

AB	J AND J	**250MG**	**N60618 002**
AB		**250MG**	**N62279 002**
AB		**500MG**	**N60618 003**
AB		**500MG**	**N62279 003**
		125MG	N60618 001
		125MG	N62279 001
AB	JOHNSON RW	**250MG**	**N60618 002**
AB		**250MG**	**N62279 002**
AB		**500MG**	**N60618 003**
AB		**500MG**	**N62279 003**
		125MG	N60618 001
		125MG	N62279 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	AMIDE PHARM	EQ 1MG BASE	N74673 001	FEB 28, 1997
AB		EQ 2MG BASE	N74673 002	FEB 28, 1997
AB	MYLAN	EQ 1MG BASE	N74796 001	JAN 27, 1997
AB		EQ 2MG BASE	N74796 002	JAN 27, 1997
AB	ROYCE LABS	EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997

HALCINONIDE

CREAM; TOPICAL

	HALOG			
	WESTWOOD SQUIBB	0.025%	N17818 001	
	@	0.025%	N17818 001	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALDOL			
+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986
+		EQ 100MG BASE/ML	N18701 002	JAN 31, 1997
	HALDOL DECANOATE 100			
+	JOHNSON RW	EQ 100MG BASE/ML	N18701 002	OCT 31, 1989
	HALDOL DECANOATE 50			
+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP FLUSH KIT IN PLASTIC CONTAINER			
AP	FUJISAWA	10 UNITS/ML	N17029 017	DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP FLUSH KIT IN PLASTIC CONTAINER			
AP	FUJISAWA	100 UNITS/ML	N17029 018	DEC 05, 1985
	@	10 UNITS/ML	N17029 017	DEC 05, 1985
	@	100 UNITS/ML	N17029 018	DEC 05, 1985
	HEPARIN LOCK FLUSH			
AP	ABBOTT	10 UNITS/ML	N40082 001	FEB 28, 1995
AP		10 UNITS/ML	N88097 001	APR 28, 1983
AP		10 UNITS/ML	N88346 001	MAY 18, 1983
AP		100 UNITS/ML	N40082 002	FEB 28, 1995
AP		100 UNITS/ML	N88098 001	APR 28, 1983
AP		100 UNITS/ML	N88347 001	MAY 18, 1983
AP	SANOFI WINTHROP	10 UNITS/ML	N40082 001	FEB 28, 1995
AP		100 UNITS/ML	N40082 002	FEB 28, 1995
AP	STERLING WINTHROP	10 UNITS/ML	N88097 001	APR 28, 1983
AP		10 UNITS/ML	N88346 001	MAY 18, 1983
AP		100 UNITS/ML	N88098 001	APR 28, 1983
AP		100 UNITS/ML	N88347 001	MAY 18, 1983
	HEPARIN SODIUM			
AP	ABBOTT	2,500 UNITS/ML	N88099 001	APR 28, 1983
AP		5,000 UNITS/ML	N88100 001	APR 28, 1983
AP		10,000 UNITS/ML	N40095 001	JUL 26, 1996
AP	FUJISAWA	20,000 UNITS/ML	N17029 004	
AP	SANOFI WINTHROP	10,000 UNITS/ML	N40095 001	JUL 26, 1996
AP	STERIS	1,000 UNITS/ML	N17064 002	
@		1,000 UNITS/ML	N17064 002	
AP	STERLING WINTHROP	2,500 UNITS/ML	N88099 001	APR 28, 1983

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM			
AP	STERLING WINTHROP	**5,000 UNITS/ML**	**N88100 001**	
			APR 28, 1983	
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	**10,000 UNITS/100ML**	**N19339 003**	
			MAR 27, 1985	
	@	10,000 UNITS/100ML	N19339 003	
			MAR 27, 1985	
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	**5,000 UNITS/100ML**	**N19339 001**	
			MAR 27, 1985	
	@	5,000 UNITS/100ML	N19339 001	
			MAR 27, 1985	
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	**5,000 UNITS/100ML**	**N19339 004**	
			MAR 27, 1985	
AP		**10,000 UNITS/100ML**	**N19339 002**	
			MAR 27, 1985	
	@	5,000 UNITS/100ML	N19339 004	
			MAR 27, 1985	
	@	10,000 UNITS/100ML	N19339 002	
			MAR 27, 1985	
	HEPARIN SODIUM PRESERVATIVE FREE			
AP +	ABBOTT	**10,000 UNITS/ML**	**N89522 001**	
			MAY 04, 1987	
AP +	STERLING WINTHROP	**10,000 UNITS/ML**	**N89522 001**	
			MAY 04, 1987	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

	HYCODAN			
AA +	DUPONT MERCK	**1.5MG/5ML;5MG/5ML**	**N05213 002**	
			JUL 26, 1988	
AA +	ENDO PHARMS	**1.5MG/5ML;5MG/5ML**	**N05213 002**	
			JUL 26, 1988	
	HYDROPANE			
AA	HALSEY	**1.5MG/5ML;5MG/5ML**	**N88066 001**	
			JUN 28, 1985	
	@	1.5MG/5ML;5MG/5ML	N88066 001	
			JUN 28, 1985	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYCODAN			
AA +	DUPONT MERCK	**1.5MG;5MG**	**N05213 001**	
			JUL 26, 1988	
AA +	ENDO PHARMS	**1.5MG;5MG**	**N05213 001**	
			JUL 26, 1988	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDRALAZINE HCL			
AP	LUITPOLD	**20MG/ML**	**N40136 001**	
			JUN 30, 1997	

TABLET; ORAL

	HYDRALAZINE HCL			
AA	HALSEY	**25MG**	**N89130 001**	
			JAN 15, 1986	
AA		**100MG**	**N89178 001**	
			JAN 15, 1986	
	@	25MG	N89130 001	
			JAN 15, 1986	
	@	100MG	N89178 001	
			JAN 15, 1986	
AA	PUREPAC PHARM	**25MG**	**N88177 001**	
			JUL 29, 1983	
	@	25MG	N88177 001	
			JUL 29, 1983	
	@ ZENITH GOLDLINE	10MG	N84443 001	
	@	25MG	N84437 001	
	@	50MG	N84469 002	
	@	100MG	N84581 001	
AA	ZENITH LABS	**10MG**	**N84443 001**	
AA		**25MG**	**N84437 001**	
AA		**50MG**	**N84469 002**	
AA		**100MG**	**N84581 001**	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50			
	@ ZENITH GOLDLINE	100MG;50MG	N88358 001	
			APR 10, 1984	
	@ ZENITH LABS	**100MG;50MG**	**N88358 001**	
			APR 10, 1984	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25			
	@ ZENITH GOLDLINE	25MG;25MG	N88356 001	APR 10, 1984
AB	ZENITH LABS	**25MG;25MG**	**N88356 001**	APR 10, 1984
	HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50			
	@ ZENITH GOLDLINE	50MG;50MG	N88357 001	APR 10, 1984
AB	ZENITH LABS	**50MG;50MG**	**N88357 001**	APR 10, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE			
	@ ZENITH GOLDLINE	25MG;15MG;0.1MG	N84291 001	
BP	ZENITH LABS	25MG;15MG;0.1MG	N84291 001	
	HYDROSERPINE PLUS (R-H-H)			
	@ ZENITH GOLDLINE	25MG;15MG;0.1MG	N83877 001	
BP	ZENITH LABS	25MG;15MG;0.1MG	N83877 001	
	UNIPRES			
BP	SOLVAY	25MG;15MG;0.1MG	N86298 001	
	@	25MG;15MG;0.1MG	N86298 001	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE		
	@ ZENITH GOLDLINE	50MG	N84658 001
	@ ZENITH LABS	50MG	N84658 001

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	IRBESARTAN-HYDROCHLOROTHIAZIDE			
	@ SANOFI	12.5MG;75MG	N20758 001	SEP 30, 1997
+		12.5MG;150MG	N20758 002	SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	PUREPAC PHARM	**15MG;250MG**	**N70853 001**	OCT 08, 1986
AB		**25MG;250MG**	**N70688 001**	APR 24, 1986
AB		**30MG;500MG**	**N70854 001**	OCT 08, 1986
	@	15MG;250MG	N70853 001	OCT 08, 1986
	@	25MG;250MG	N70688 001	APR 24, 1986
	@	30MG;500MG	N70854 001	OCT 08, 1986
	@ ZENITH GOLDLINE	15MG;250MG	N71458 001	MAR 08, 1988
	@	25MG;250MG	N71459 001	MAR 08, 1988
	@	30MG;500MG	N71460 001	MAR 08, 1988
	@	50MG;500MG	N71461 001	MAR 08, 1988
	@ ZENITH LABS	15MG;250MG	N71458 001	MAR 08, 1988
	@	25MG;250MG	N71459 001	MAR 08, 1988
	@	30MG;500MG	N71460 001	MAR 08, 1988
	@	50MG;500MG	N71461 001	MAR 08, 1988

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIRETIC			
	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001	JUN 27, 1997
+		25MG;15MG	N20729 002	JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE			
	@ ZENITH GOLDLINE	25MG;40MG	N71552 001	DEC 01, 1988

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

@	ZENITH GOLDLINE	25MG;80MG	N71553 001 DEC 01, 1988
AB	ZENITH LABS	25MG;40MG	N71552 001 DEC 01, 1988
AB		25MG;80MG	N71553 001 DEC 01, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE

@	ZENITH GOLDLINE	25MG;0.1MG	N83572 001
@		25MG;0.125MG	N83571 001
@		50MG;0.1MG	N83568 001
@		50MG;0.125MG	N83573 001
BP	ZENITH LABS	25MG;0.125MG	N83571 001
BP		50MG;0.125MG	N83573 001
		25MG;0.1MG	N83572 001
		50MG;0.1MG	N83568 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

@	ZENITH GOLDLINE	25MG;25MG	N87004 002 MAY 24, 1982
AB	ZENITH LABS	25MG;25MG	N87004 002 MAY 24, 1982

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	25MG;37.5MG	N74821 001 JUN 05, 1997
AB	NOVARTIS	25MG;37.5MG	N74857 001 SEP 09, 1997

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

B*	PAR PHARM	50MG;75MG	N72337 001 MAY 11, 1988

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
VICOPROFEN

+	KNOLL PHARM	7.5MG;200MG	N20716 001 SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
HYCOMINE

+	DUPONT MERCK	5MG/5ML;25MG/5ML	N19410 001 AUG 17, 1990
+	ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001 AUG 17, 1990

HYCOMINE PEDIATRIC

	DUPONT MERCK	2.5MG/5ML;12.5MG/5ML	N19411 001 AUG 17, 1990
	ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N19411 001 AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL
DERMACORT

AT	MONARCH PHARMS	1%	N83011 002
AT	SOLVAY	1%	N83011 002

HYDROCORTISONE

@	ALPHARMA	2.5%	N89754 001 FEB 01, 1989
AT	NMC	2.5%	N89754 001 FEB 01, 1989

PROCTOCORT

AT	MONARCH PHARMS	1%	N83011 001
AT	SOLVAY	1%	N83011 001

SYNACORT

AT	MEDICIS	1%	N87458 001
AT		2.5%	N87457 001
@		0.5%	N87459 001
AT	SYNTEX	1%	N87458 001
AT		2.5%	N87457 001
@		0.5%	N87459 001

TABLET; ORAL
HYDROCORTISONE

BP	PUREPAC PHARM	10MG	N84247 003 AUG 31, 1982

HYDROCORTISONE

TABLET; ORAL
HYDROCORTISONE

BP	PUREPAC PHARM	20MG		N84247 002
	@	10MG		N84247 003 AUG 31, 1982
	@	20MG		N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; AURICULAR (OTIC)
CORTISPORIN

AT	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N50479 001

OTOCORT

@ STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N60730 002

SOLUTION/DROPS; OTIC
CORTISPORIN

AT	+ GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N50479 001

OTOCORT

AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N60730 002

SUSPENSION/DROPS; AURICULAR (OTIC)
OTOCORT

	@ STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62521 001 JUL 11, 1985

PEDIOTIC

AT	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62822 001 SEP 29, 1987

SUSPENSION/DROPS; OTIC
OTOCORT

AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62521 001 JUL 11, 1985

PEDIOTIC

AT	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62822 001 SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL
ALPHADERM

	@ BIOGLAN	1%;10%		N86008 001
	@ VIVAN	1%;10%		N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HEMSOL-HC

AT	ABLE	1%		N81274 001 JUN 19, 1992
	+	1%		N81274 001 JUN 19, 1992

HYDROCORTISONE ACETATE

AT	+ PUREPAC PHARM	1%		N86052 001
	@	1%		N86052 001

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

BP	AKORN	25MG/ML		N09637 001
BP		50MG/ML		N09637 002
	@	25MG/ML		N09637 001
	@	50MG/ML		N09637 002
BP	STERIS	25MG/ML		N83759 001
BP		50MG/ML		N83759 002
	@	25MG/ML		N83759 001
	@	50MG/ML		N83759 002

HYDROCORTONE

BP	+ MERCK SHARP DOHME	50MG/ML		N08228 004
	+	50MG/ML		N08228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN

	+ GLAXO WELLCOME	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50218 001 AUG 09, 1985
	+ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50218 001 AUG 09, 1985

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL
PANDEL
+ SAVAGE LABS 0.1% N20453 001 FEB 28, 1997

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID LIPOCREAM
YAMANOUCHI 0.1% N20769 001 SEP 08, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP	ELKINS SINN	EQ 1GM BASE/VIAL	N87569 001
@		EQ 1GM BASE/VIAL	N87569 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE AND HYDROFLUMETHIAZIDE

@	ZENITH GOLDLINE	50MG;0.125MG	N88932 001 JAN 11, 1985
BP	ZENITH LABS	50MG;0.125MG	N88932 001 JAN 11, 1985

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP	ABBOTT	10MG/ML	N74598 001 JUN 19, 1997
AP	SANOFI	10MG/ML	N74598 001 JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	ABBOTT	25MG/ML	N87416 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	ABBOTT	50MG/ML	N87546 001
AP	STERLING WINTHROP	25MG/ML	N87416 001
AP		50MG/ML	N87546 001

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY	25MG	N89117 001 MAY 02, 1988
@		25MG	N89117 001 MAY 02, 1988
AB	KV PHARM	10MG	N87819 001 JUN 23, 1982
AB		25MG	N87820 001 JUN 23, 1982
AB		50MG	N87821 001 JUN 23, 1982
AB		100MG	N87822 001 JUN 23, 1982
@		10MG	N87819 001 JUN 23, 1982
@		25MG	N87820 001 JUN 23, 1982
@		50MG	N87821 001 JUN 23, 1982
@		100MG	N87822 001 JUN 23, 1982
AB	PUREPAC PHARM	10MG	N88120 001 SEP 25, 1984
AB		25MG	N88121 001 SEP 25, 1984
AB		50MG	N88122 001 SEP 25, 1984
@		10MG	N88120 001 SEP 25, 1984
@		25MG	N88121 001 SEP 25, 1984
@		50MG	N88122 001 SEP 25, 1984
@	ZENITH GOLDLINE	10MG	N87216 001
@		25MG	N87410 001
@		50MG	N87411 001
AB	ZENITH LABS	10MG	N87216 001
AB		25MG	N87410 001
AB		50MG	N87411 001

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HY-PAM			
AB	EON	EQ 25MG HCL	N87479 001	
	HYDROXYZINE PAMOATE			
AB	EON	EQ 25MG HCL	N87479 001	

IBUPROFEN

SUSPENSION; ORAL

	IBU			
BX	KNOLL PHARM	100MG/5ML	N19784 001	DEC 18, 1989
@		100MG/5ML	N19784 001	DEC 18, 1989

TABLET; ORAL

	IBUPROFEN			
AB	PUREPAC PHARM	300MG	N71123 001	SEP 19, 1986
AB		400MG	N71124 001	SEP 19, 1986
AB		600MG	N71125 001	SEP 19, 1986
AB		800MG	N71964 001	FEB 01, 1988
@		300MG	N71123 001	SEP 19, 1986
@		400MG	N71124 001	SEP 19, 1986
@		600MG	N71125 001	SEP 19, 1986
@		800MG	N71964 001	FEB 01, 1988
	MOTRIN			
AB	MCNEIL	300MG	N17463 003	
AB		400MG	N17463 002	
AB		600MG	N17463 004	
AB +		800MG	N17463 005	MAY 22, 1985
AB	PHARMACIA AND UPJOHN	300MG	N17463 003	
AB		400MG	N17463 002	
AB		600MG	N17463 004	
AB +		800MG	N17463 005	MAY 22, 1985

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	IDAMYCIN PFS			
+	PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997

IFOSFAMIDE

INJECTABLE; INJECTION

	IFEX			
+	BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001	DEC 30, 1988
+		3GM/VIAL	N19763 002	DEC 30, 1988
@		1GM/VIAL	N19763 001	DEC 30, 1988
@		3GM/VIAL	N19763 002	DEC 30, 1988

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

	IFEX/MESNEX KIT			
+	BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003	OCT 10, 1992
+		3GM/VIAL;100MG/ML	N19763 004	OCT 10, 1992

IMIQUIMOD

CREAM; TOPICAL

	ALDARA			
+	3M	5%	N20723 001	FEB 27, 1997

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	MYLAN	1.25MG	N74461 002	MAR 26, 1997
AB	NOVOPHARM	1.25MG	N74665 001	APR 04, 1997

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE
AB NOVOPHARM **2.5MG** **N74665 002**
APR 04, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE
> DLT > MEDI PHYSICS 1mCi/ML N19044 001
> DLT > DEC 23, 1985
> ADD > NYCOMED AMERSHAM 1mCi/ML N19044 001
> ADD > DEC 23, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL
MPI INDIUM DTPA IN 111
> DLT > MEDI PHYSICS 1mCi/ML N17707 001
> DLT > FEB 18, 1982
> ADD > NYCOMED AMERSHAM 1mCi/ML N17707 001
> ADD > FEB 18, 1982

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN
\+ AKORN 25MG/VIAL N11525 001
\+ 50MG/VIAL N11525 002
\+ BECTON DICKINSON 25MG/VIAL N11525 001
\+ 50MG/VIAL N11525 002

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
NYCOMED 55% N20808 001
AUG 29, 1997

VISIPAQUE 320
NYCOMED 65.2% N20808 002
AUG 29, 1997

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPUTOPE
BRACCO 1-2mCi/VIAL N15419 002
@ 1-2mCi/VIAL N15419 002
IODOHIPPURATE SODIUM I 131
@ CIS 0.2mCi/ML N17313 001
SORIN 0.2mCi/ML N17313 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-250
AP FUJISAWA **51%** **N74679 001**
APR 02, 1997

IOPAMIDOL-300
AP ABBOTT **61%** **N74638 001**
APR 30, 1997
AP FUJISAWA **61%** **N74679 002**
APR 02, 1997

IOPAMIDOL-300 IN PLASTIC CONTAINER
AP ABBOTT **61%** **N74637 001**
APR 03, 1997

IOPAMIDOL-370
AP FUJISAWA **76%** **N74679 003**
APR 02, 1997

ISOVUE-250
AP \+ BRACCO **51%** **N18735 007**
JUL 06, 1992
AP \+ **51%** **N20327 002**
OCT 12, 1994

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N12968 001
@ 3GM/PACKET N12968 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT
AN \+ BOEHRINGER INGELHEIM **0.02%** **N20228 001**
SEP 29, 1993

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN DEY 0.02% N74755 001 JAN 10, 1997

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI 75MG N20757 001 SEP 30, 1997
150MG N20757 002 SEP 30, 1997
+ 300MG N20757 003 SEP 30, 1997

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
AN ALPHARMA 1% N87101 001
@ 1% N87101 001

ISOFLUROPHATE

OINTMENT; OPHTHALMIC
FLOROPRYL
+ MERCK SHARP DOHME 0.025% N10656 001
@ 0.025% N10656 001

ISONIAZID

SYRUP; ORAL
ISONIAZID
AA + CAROLINA MEDCL 50MG/5ML N88235 001 NOV 10, 1983
+ 50MG/5ML N88235 001 NOV 10, 1983
AA MIKART 50MG/5ML N81118 001 JUL 21, 1997
LANIAZID
AA LANNETT 50MG/5ML N89243 001 FEB 03, 1986

ISONIAZID

SYRUP; ORAL
LANIAZID
@ LANNETT 50MG/5ML N89243 001 FEB 03, 1986

TABLET; ORAL
ISONIAZID
AA MIKART 100MG N40090 001 JUN 26, 1997
AA 300MG N40090 002 JUN 26, 1997
@ ZENITH GOLDLINE 100MG N80270 001
@ 300MG N83610 001
@ ZENITH LABS 100MG N80270 001
@ 300MG N83610 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISOPROTERENOL HCL
BN + 3M 0.12MG/INH N10375 004
+ 0.12MG/INH N10375 004
BN ALPHARMA 0.12MG/INH N85904 001
@ 0.12MG/INH N85904 001

INJECTABLE; INJECTION
ISUPREL
AP + ABBOTT 0.2MG/ML N10515 001
AP + SANOFI WINTHROP 0.2MG/ML N10515 001

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX
+ JANSSEN 10MG/ML N20657 001 FEB 21, 1997

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL
AP ABBOTT EQ 50MG BASE/ML N74549 001 JUN 27, 1996

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL

AP	ABBOTT	EQ 100MG BASE/ML	N74549 002	
			JUN 27, 1996	> DLT >
AP	SANOFI WINTHROP	EQ 50MG BASE/ML	N74549 001	> ADD >
			JUN 27, 1996	
AP		EQ 100MG BASE/ML	N74549 002	
			JUN 27, 1996	

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	ABBOTT	15MG/ML	N74801 001
			JUN 05, 1997
AP		15MG/ML	N74802 001
			JUN 05, 1997
AP		30MG/ML	N74801 002
			JUN 05, 1997
AP		30MG/ML	N74802 002
			JUN 05, 1997

TORADOL

AP	+ SYNTEX	15MG/ML	N19698 001
			NOV 30, 1989
AP	+	30MG/ML	N19698 002
			NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC
> ADD > ACULAR PRESERVATIVE FREE

> ADD >	+ SYNTEX	0.5%	N20811 001
> ADD >			NOV 03, 1997

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	CHELSEA LABS	10MG	N74955 001
			SEP 19, 1997
AB	MYLAN	10MG	N74761 001
			MAY 16, 1997
AB	ROXANE	10MG	N74790 001
			JUN 26, 1997
AB	TEVA	10MG	N74754 001
			MAY 16, 1997

TORADOL

AB	+ SYNTEX	10MG	N19645 001
			DEC 20, 1991

KRYPTON, KR-81M

GAS; INHALATION
MPI KRYPTON 81M GAS GENERATOR

	MEDI PHYSICS	N/A	N18088 001
> ADD >	NYCOMED AMERSHAM	N/A	N18088 001

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
COMBIVIR

+	GLAXO WELLCOME	150MG;300MG	N20857 001
			SEP 26, 1997

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001
			MAY 10, 1995
+		30MG	N20406 002
			MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001
			MAY 10, 1995
+		30MG	N20406 002
			MAY 10, 1995

LETROZOLE

TABLET; ORAL
FEMARA

+	NOVARTIS	2.5MG	N20726 001
			JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001	
			JUN 25, 1997	
AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001	
			MAY 23, 1995	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

	+	BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995
AP		GENSIA	EQ 350MG BASE/VIAL	N40174 001 JUN 12, 1997
AP	+	IMMUNEX	EQ 350MG BASE/VIAL	N08107 005 APR 05, 1989
AP		PHARMACHEMIE	EQ 50MG BASE/VIAL	N89628 001 APR 17, 1997
AP			EQ 100MG BASE/VIAL	N89915 001 APR 17, 1997

TABLET; ORAL
LEUCOVORIN CALCIUM

AB	PAR PHARM	EQ 5MG BASE	N74544 001 AUG 28, 1997
AB		EQ 25MG BASE	N74544 002 AUG 28, 1997
AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001 MAR 28, 1997
AB		EQ 25MG BASE	N73101 001 MAR 28, 1997

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3

+	TAP HOLDINGS	11.25MG/VIAL	N20708 001 MAR 07, 1997

LUPRON DEPOT-4

+	TAP HOLDINGS	30MG/VIAL	N20517 002 MAY 30, 1997

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	ABBOTT	1%	N40013 001 JUN 23, 1995
AP		2%	N40078 001 JUN 23, 1995
AP	SANOFI WINTHROP	1%	N40013 001 JUN 23, 1995

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	SANOFI WINTHROP	2%	N40078 001 JUN 23, 1995

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL

	JONES MEDCL INDS	EQ 0.005MG BASE	N10379 001
		EQ 0.025MG BASE	N10379 002
+		EQ 0.05MG BASE	N10379 003
	SMITHKLINE BEECHAM	EQ 0.005MG BASE	N10379 001
		EQ 0.025MG BASE	N10379 002
+		EQ 0.05MG BASE	N10379 003

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID

	SOLVAY	300MG	N18027 001
+		300MG	N18027 001

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

AP	ABBOTT	2MG/ML	N74243 001 APR 12, 1994
AP		2MG/ML	N74300 001 APR 12, 1994
AP		4MG/ML	N74243 002 APR 12, 1994
AP		4MG/ML	N74300 003 MAR 19, 1997
AP	STERLING WINTHROP	2MG/ML	N74243 001 APR 12, 1994
AP		2MG/ML	N74300 001 APR 12, 1994
AP		4MG/ML	N74243 002 APR 12, 1994

SOLUTION; ORAL
LORAZEPAM

+	ROXANE	0.5MG/5ML	N74648 001 MAR 18, 1997

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL
LOXITANE C

> ADD >	+	COCENSYS	EQ 25MG BASE/ML	N17658 001
> DLT >	+	LEDERLE	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION
LOXITANE IM

> ADD >	+	COCENSYS	EQ 50MG BASE/ML	N18039 001
> DLT >	+	LEDERLE	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXITANE

> ADD >	AB	COCENSYS	EQ 5MG BASE	N17525 001
> ADD >	AB		EQ 10MG BASE	N17525 002
> ADD >	AB	+	EQ 25MG BASE	N17525 003
> ADD >	AB		EQ 50MG BASE	N17525 004
> DLT >	AB	LEDERLE	EQ 5MG BASE	N17525 001
> DLT >	AB		EQ 10MG BASE	N17525 002
> DLT >	AB	+	EQ 25MG BASE	N17525 003
> DLT >	AB		EQ 50MG BASE	N17525 004

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

		FUJISAWA	500MG/ML	N19316 001 SEP 08, 1986
	+		500MG/ML	N19316 001 SEP 08, 1986

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

		ABBOTT	1GM/100ML	N20488 001 JUL 11, 1995
	+		1GM/100ML	N20488 001 JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

		ABBOTT	4GM/100ML	N20309 001 JUN 24, 1994
			80MG/ML	N20309 002 JUN 24, 1994
	+		4GM/100ML	N20309 001 JUN 24, 1994
	+		80MG/ML	N20309 002 JUN 24, 1994

MALATHION

LOTION; TOPICAL
OVIDE

> DLT >	+	GENDERM	0.5%	N18613 001 AUG 02, 1982
> ADD >	@		0.5%	N18613 001 AUG 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION
TESLASCAN

> ADD >	+	NYCOMED	37.9MG/ML	N20652 001 NOV 26, 1997

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

AA		KV PHARM	12.5MG	N85524 001
AA			25MG	N85523 001
	@		12.5MG	N85524 001
	@		25MG	N85523 001
AA		VINTAGE PHARMS	12.5MG	N40179 001 JAN 30, 1997
AA			25MG	N40179 002 JAN 30, 1997
AA		ZENITH GOLDLINE	12.5MG	N84975 001
AA			25MG	N84657 001
	@		12.5MG	N83784 001
AA		ZENITH LABS	12.5MG	N83784 001
AA			12.5MG	N84975 001
AA			25MG	N84657 001

TABLET, CHEWABLE; ORAL
MECLIZINE HCL

	@	ZENITH GOLDLINE	25MG	N84976 001
AA		ZENITH LABS	25MG	N84976 001

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
HUMEGON

AB	+	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	HUMEGON			
AB	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001	SEP 01, 1994
AB	+	150 IU/VIAL;150 IU/VIAL	N20328 002	SEP 01, 1994
AB		150 IU/VIAL;150 IU/VIAL	N20328 002	SEP 01, 1994
	REPRONAL			
AB	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001	JAN 30, 1997
AB		75 IU/VIAL;75 IU/VIAL	N73598 001	JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL	N73599 001	JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL	N73599 001	JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERIDINE HCL			
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997

TABLET; ORAL

	MEPERIDINE HCL			
AA	ROXANE	50MG	N40110 001	MAR 12, 1997
AA		100MG	N40110 002	MAR 12, 1997
AA	ROYCE LABS	50MG	N40186 001	JUN 30, 1997
AA		100MG	N40186 002	JUN 30, 1997

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE			
AA	PUREPAC PHARM	200MG	N84804 001	
AA		400MG	N84804 002	
	@	200MG	N84804 001	
	@	400MG	N84804 002	
	@ ZENITH GOLDLINE	600MG	N84181 001	

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE			
AA	ZENITH LABS	600MG	N84181 001	

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	JVL	10MG/5ML	N74702 001	MAR 24, 1997
AA	MORTON GROVE	10MG/5ML	N71656 001	OCT 13, 1987
AA		10MG/5ML	N74702 001	MAR 24, 1997
	@	10MG/5ML	N71656 001	OCT 13, 1987

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
	BRISTOL MYERS SQUIBB	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994
		500MG	N20357 001	MAR 03, 1995
	+	850MG	N20357 002	MAR 03, 1995

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION

	PROVOCHOLINE			
	METHAPHARM	100MG/VIAL	N19193 001	OCT 31, 1986
	ROCHE	100MG/VIAL	N19193 001	OCT 31, 1986

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB	APPLIED ANAL	25MG	N40011 001 JUL 17, 1997
AB		50MG	N40011 002 JUL 17, 1997

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA	PUREPAC PHARM	500MG	N85718 001
AA		750MG	N85718 002
@		500MG	N85718 001
@		750MG	N85718 002
@	ZENITH GOLDLINE	500MG	N84648 001
@		750MG	N84649 001
AA	ZENITH LABS	500MG	N84648 001
AA		750MG	N84649 001

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED

AP	BRISTOL MYERS	EQ 25MG BASE/ML	N89887 001 APR 14, 1989
@	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

METHOXSALEN

CAPSULE; ORAL
OXSORALEN-ULTRA

+	ICN	10MG	N19600 001 OCT 30, 1986

CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA

+	ICN	10MG	N19600 001 OCT 30, 1986

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

AB	ZENITH GOLDLINE	2.5MG	N87913 001 JUN 03, 1982
@		5MG	N87786 001 MAY 18, 1982
AB	ZENITH LABS	2.5MG	N87913 001 JUN 03, 1982
AB		5MG	N87786 001 MAY 18, 1982

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	HALSEY	125MG	N71751 001 MAR 28, 1988
AB		250MG	N71752 001 MAR 28, 1988
@		125MG	N71751 001 MAR 28, 1988
@		250MG	N71752 001 MAR 28, 1988
AB	PUREPAC PHARM	125MG	N70749 001 FEB 07, 1986
AB		250MG	N70750 001 FEB 07, 1986
AB		500MG	N70452 001 FEB 07, 1986
@		125MG	N70749 001 FEB 07, 1986
@		250MG	N70750 001 FEB 07, 1986
@		500MG	N70452 001 FEB 07, 1986

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL

AB	DANBURY PHARMA	5MG	N40220 001 AUG 29, 1997
AB		10MG	N40220 002 AUG 29, 1997

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL

AB	DANBURY PHARMA	20MG	N40220 003	AUG 29, 1997

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL

AB	PHARMACIA AND UPJOHN	8MG	N11153 004	

METHYLPREDNISOLONE

AB	CHELSEA LABS	4MG	N40232 001	OCT 16, 1997
AB	INVAMED	4MG	N40194 001	OCT 31, 1997
AB	TRIGEN	4MG	N40189 001	OCT 31, 1997
AB		8MG	N40189 002	OCT 31, 1997

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	ABBOTT	EQ 5MG BASE/ML	N74147 001	AUG 02, 1996
AP	FAULDING	EQ 5MG BASE/ML	N71990 001	JAN 18, 1989
@		EQ 5MG BASE/ML	N71990 001	JAN 18, 1989
AP	SANOFI WINTHROP	EQ 5MG BASE/ML	N74147 001	AUG 02, 1996

SOLUTION; ORAL
METOCLOPRAMIDE

AA	JVL	EQ 5MG BASE/5ML	N74703 001	OCT 31, 1997

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997

METOLAZONE

TABLET; ORAL
MYKROX

	MEDEVA	0.5MG	N19532 001	OCT 30, 1987
+		0.5MG	N19532 001	OCT 30, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	ABBOTT	1MG/ML	N74133 001	DEC 21, 1993
AP	STERLING WINTHROP	1MG/ML	N74133 001	DEC 21, 1993

METRONIDAZOLE

CREAM; TOPICAL
NORITATE

+	DERMIK LABS	1%	N20743 001	SEP 26, 1997

GEL; VAGINAL
METROGEL-VAGINAL

+	3M	0.75%	N20208 001	AUG 17, 1992
+	CURATEK	0.75%	N20208 001	AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

AP	STERIS	500MG/100ML	N70042 001	DEC 20, 1984
@		500MG/100ML	N70042 001	DEC 20, 1984

> ADD >
> ADD >
> ADD >
> ADD >

TABLET, EXTENDED RELEASE; ORAL
FLAGYL ER

+	SEARLE	750MG	N20868 001	NOV 26, 1997

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	150MG	N74711 001 FEB 26, 1997
AB		200MG	N74711 002 FEB 26, 1997
AB		250MG	N74711 003 FEB 26, 1997

MIBEFRADIL DIHYDROCHLORIDE

TABLET; ORAL
POSICOR

	ROCHE	EQ 50MG BASE	N20689 001 JUN 20, 1997
+		EQ 100MG BASE	N20689 002 JUN 20, 1997

MICONAZOLE

INJECTABLE; INJECTION
MONISTAT

+	JANSSEN	10MG/ML	N18040 001
@		10MG/ML	N18040 001

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

+	J AND J	2%	N17494 001
+	JOHNSON RW	2%	N17494 001

LOTION; TOPICAL
MONISTAT-DERM

@	J AND J	2%	N17739 001
@	JOHNSON RW	2%	N17739 001

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL

	LEDERLE	EQ 50MG BASE	N50451 003 AUG 10, 1982

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL

+	LEDERLE	EQ 100MG BASE	N50451 002 AUG 10, 1982
@		EQ 50MG BASE	N50451 003 AUG 10, 1982
@		EQ 100MG BASE	N50451 002 AUG 10, 1982

MIRTAZAPINE

TABLET; ORAL
REMERON

+	ORGANON	30MG	N20415 002 JUN 14, 1996
		30MG	N20415 002 JUN 14, 1996
+		45MG	N20415 003 MAR 17, 1997

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL
MOBAN

@	DUPONT MERCK	5MG	N17111 001
@		10MG	N17111 002
@		25MG	N17111 003
@	ENDO PHARMS	5MG	N17111 001
@		10MG	N17111 002
@		25MG	N17111 003

CONCENTRATE; ORAL
MOBAN

+	DUPONT MERCK	20MG/ML	N17938 001
+	ENDO PHARMS	20MG/ML	N17938 001

TABLET; ORAL
MOBAN

	DUPONT MERCK	5MG	N17111 004
		10MG	N17111 005
+		25MG	N17111 006
+		50MG	N17111 007
+		100MG	N17111 008
	ENDO PHARMS	5MG	N17111 004
		10MG	N17111 005

MOLINDONE HYDROCHLORIDE

TABLET; ORAL
MOBAN

+	ENDO PHARMS	25MG		N17111 006
		50MG		N17111 007
+		100MG		N17111 008

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY		N20762 001 OCT 01, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL
CELLCEPT

+	SYNTEX	500MG		N50723 001 JUN 19, 1997

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NUBAIN

AP	+	DUPONT MERCK	**10MG/ML**	**N18024 001**
AP	+		**20MG/ML**	**N18024 002** MAY 27, 1982
AP	+	ENDO PHARMS	**10MG/ML**	**N18024 001**
AP	+		**20MG/ML**	**N18024 002** MAY 27, 1982

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP		ABBOTT	**0.02MG/ML**	**N70171 001** SEP 24, 1986
AP			**0.4MG/ML**	**N70172 001** SEP 24, 1986
AP		STERLING WINTHROP	**0.02MG/ML**	**N70171 001** SEP 24, 1986
AP			**0.4MG/ML**	**N70172 001** SEP 24, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NARCAN

AP	+	DUPONT MERCK	**0.02MG/ML**	**N16636 002**
AP	+		**0.4MG/ML**	**N16636 001**
AP	+		**1MG/ML**	**N16636 003** JUN 14, 1982
AP	+	ENDO PHARMS	**0.02MG/ML**	**N16636 002**
AP	+		**0.4MG/ML**	**N16636 001**
AP	+		**1MG/ML**	**N16636 003** JUN 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB		ROYCE LABS	**EQ 0.5MG BASE; EQ 50MG BASE**	**N74736 001** JAN 21, 1997

TALWIN NX

AB	+	SANOFI	**EQ 0.5MG BASE; EQ 50MG BASE**	**N18733 001** DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO		STERIS	**50MG/ML**	**N87598 001** OCT 06, 1983
AO			**100MG/ML**	**N87599 001** OCT 06, 1983
	@		50MG/ML	N87598 001 OCT 06, 1983
	@		100MG/ML	N87599 001 OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE

+		FISONS	1.75MG/INH	**N19660 001** DEC 30, 1992
+		RHONE POULENC RORER	1.75MG/INH	N19660 001 DEC 30, 1992

NEDOCROMIL SODIUM

SOLUTION; INHALATION
TILADE
+ RHONE POULENC RORER 0.5% N20750 001 OCT 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE
@ BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994
+ 50MG N20152 001 DEC 22, 1994

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT
+ AGOURON EQ 50MG BASE/SCOOPFUL N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
+ AGOURON EQ 250MG BASE N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK 100% N61579 001
100% N61579 001
NEOMYCIN SULFATE
AA PADDOCK 100% N62385 001 JUN 01, 1982

NIACIN

TABLET; ORAL
NIACIN
AA HALSEY 500MG N83453 001
@ 500MG N83453 001
AA PUREPAC PHARM 500MG N83271 001

NIACIN

TABLET; ORAL
NIACIN
@ PUREPAC PHARM 500MG N83271 001
@ ZENITH GOLDLINE 500MG N83180 001
@ ZENITH LABS 500MG N83180 001

TABLET, EXTENDED RELEASE; ORAL
NIASPAN
+ KOS 375MG N20381 001 JUL 28, 1997
+ 500MG N20381 002 JUL 28, 1997
+ 750MG N20381 003 JUL 28, 1997
+ 1GM N20381 004 JUL 28, 1997

NIASPAN TITRATION STARTER PACK
+ KOS 375MG;500MG;750MG N20381 005 JUL 28, 1997

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL
AB + NOVARTIS 7MG/24HR N20076 001 NOV 27, 1991
AB + 14MG/24HR N20076 002 NOV 27, 1991
AB + 21MG/24HR N20076 003 NOV 27, 1991
NICOTINE
AB SANO 7MG/24HR N74645 001 OCT 20, 1997
AB 14MG/24HR N74611 001 OCT 20, 1997
AB 21MG/24HR N74612 001 OCT 20, 1997

INHALANT; INHALATION
NICOTROL
+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE N20714 001 MAY 02, 1997

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN
@ ZENITH GOLDLINE 50MG N80078 002
@ 100MG N80078 001
@ ZENITH LABS 50MG N80078 002
@ 100MG N80078 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTION
AB MYLAN **100MG** **N74967 002**
JUL 09, 1997

NITROFURANTOIN
AB MYLAN **50MG** **N74967 001**
JUL 09, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
+ ABBOTT EQ 1MG BASE/ML N07513 001
+ SANOFI WINTHROP EQ 1MG BASE/ML N07513 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB INVAMED **EQ 10MG BASE** **N74835 001**
JUN 30, 1997
AB **EQ 25MG BASE** **N74835 002**
JUN 30, 1997
AB **EQ 50MG BASE** **N74835 003**
JUN 30, 1997
AB **EQ 75MG BASE** **N74835 004**
JUN 30, 1997

NYSTATIN

CREAM; TOPICAL
MYKINAC
@ ALPHARMA 100,000 UNITS/GM N62387 001
JUL 29, 1982

NYSTATIN

CREAM; TOPICAL
MYKINAC
AT NMC **100,000 UNITS/GM** **N62387 001**
JUL 29, 1982

OINTMENT; TOPICAL
MYCOSTATIN
AT + SQUIBB **100,000 UNITS/GM** **N60571 001**
@ WESTWOOD SQUIBB 100,000 UNITS/GM N60571 001
MYKINAC
@ ALPHARMA 100,000 UNITS/GM N62731 001
SEP 22, 1986
AT NMC **100,000 UNITS/GM** **N62731 001**
SEP 22, 1986

NILSTAT
AT LEDERLE **100,000 UNITS/GM** **N61444 001**
AT + **100,000 UNITS/GM** **N61444 001**

SUSPENSION; ORAL
NYSTATIN
AA ALPHARMA **100,000 UNITS/ML** **N62571 001**
OCT 29, 1985
@ 100,000 UNITS/ML N62571 001
OCT 29, 1985

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
ZOFRAN
+ GLAXO WELLCOME EQ 4MG BASE/5ML N20605 001
JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL
AB SMITHKLINE BEECHAM **EQ 250MG BASE** **N61336 001**
AB + **EQ 250MG BASE** **N61336 001**
OXACILLIN SODIUM
AB APOTHECON **EQ 250MG BASE** **N61450 002**
AB + **EQ 500MG BASE** **N61450 001**
@ EQ 250MG BASE N61450 002
@ EQ 500MG BASE N61450 001

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
CHOLEDYL SA
+ PARKE DAVIS 600MG N86742 001
+ WARNER CHILCOTT 600MG N86742 001

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MORTON GROVE **5MG/5ML** **N74868 001**
FEB 12, 1997
AA NU PHARM **5MG/5ML** **N74997 001**
OCT 15, 1997

TABLET; ORAL
OXYBUTYNIN CHLORIDE
AB VINTAGE PHARMS **5MG** **N75079 001** >DLT> >ADD>
OCT 31, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
+ PURDUE FREDERICK 10MG N20553 001
DEC 12, 1995
+ 20MG N20553 002
DEC 12, 1995
+ 40MG N20553 003
DEC 12, 1995
+ PURDUE PHARMA 10MG N20553 001
DEC 12, 1995
+ 20MG N20553 002
DEC 12, 1995
+ 40MG N20553 003
DEC 12, 1995
+ 80MG N20553 004
JAN 06, 1997

OXYMETHOLONE

TABLET; ORAL
ANADROL-50
+ SYNTEX 50MG N16848 001
+ UNIMED 50MG N16848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
NUMORPHAN
+ DUPONT MERCK 1MG/ML N11707 002
+ 1.5MG/ML N11707 001
+ ENDO PHARMS 1MG/ML N11707 002
+ 1.5MG/ML N11707 001

SUPPOSITORY; RECTAL
NUMORPHAN
+ DUPONT MERCK 5MG N11738 004
+ ENDO PHARMS 5MG N11738 004

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
AP WYETH AYERST **10 USP UNITS/ML** **N18243 001**
@ 10 USP UNITS/ML N18243 001

SOLUTION; NASAL
SYNTOCINON
+ NOVARTIS 40 USP UNITS/ML N12285 001
@ 40 USP UNITS/ML N12285 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AB + PARKE DAVIS **EQ 250MG BASE** **N60521 001**
AB **EQ 250MG BASE** **N62310 001**
PAROMOMYCIN SULFATE
AB CARACO **EQ 250MG BASE** **N64171 001**
JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ SMITHKLINE BEECHAM EQ 10MG BASE/5ML N20710 001
JUN 25, 1997

PENICILLIN G POTASSIUM

TABLET; ORAL

	PENICILLIN G POTASSIUM			
	@ ZENITH GOLDLINE	400,000 UNITS	N60073 004	
AB	ZENITH LABS	**400,000 UNITS**	**N60073 004**	

PENICILLIN V POTASSIUM

TABLET; ORAL

	PENICILLIN V POTASSIUM			
	@ ZENITH GOLDLINE	EQ 125MG BASE	N60518 001	
	@	EQ 250MG BASE	N60518 002	
	@	EQ 500MG BASE	N60518 003	
AB	ZENITH LABS	**EQ 125MG BASE**	**N60518 001**	
AB		**EQ 250MG BASE**	**N60518 002**	
AB		**EQ 500MG BASE**	**N60518 003**	
	V-CILLIN K			
AB	+ LILLY	**EQ 125MG BASE**	**N60003 001**	
	+	EQ 125MG BASE	N60003 001	

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

	TALWIN			
	+ ABBOTT	EQ 30MG BASE/ML	N16194 001	
	+ SANOFI WINTHROP	EQ 30MG BASE/ML	N16194 001	

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	SODIUM PENTOBARBITAL			
	@ ZENITH GOLDLINE	50MG	N83461 001	
	@	100MG	N83461 002	
AA	ZENITH LABS	**50MG**	**N83461 001**	
AA		**100MG**	**N83461 002**	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	ESI LEDERLE	**400MG**	**N74877 001**	
			JUL 08, 1997	
AB	MYLAN	**400MG**	**N74425 001**	
			JUL 08, 1997	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE			
AB	PUREPAC PHARM	**400MG**	**N74878 001**	
			JUL 09, 1997	
	TRENTAL			
AB	+ HOECHST MARION RSSL	**400MG**	**N18631 001**	
			AUG 30, 1984	

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
	RHONE POULENC RORER	2MG	N20184 001	
			DEC 30, 1993	
		4MG	N20184 002	
			DEC 30, 1993	
	+	8MG	N20184 003	
			DEC 30, 1993	
	@	2MG	N20184 001	
			DEC 30, 1993	
	@	4MG	N20184 002	
			DEC 30, 1993	
	@	8MG	N20184 003	
			DEC 30, 1993	

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	BONTRIL			
BC	MALLINCKRODT	105MG	N88021 001	
			SEP 21, 1982	
	PHENDIMETRAZINE TARTRATE			
BC	GRAHAM DM	105MG	N87214 001	
			MAY 26, 1982	
BC		105MG	N88020 001	
			AUG 16, 1982	
BC		105MG	N88021 001	
			SEP 21, 1982	
BC		105MG	N88028 001	
			AUG 16, 1982	
BC		105MG	N88062 001	
			SEP 13, 1982	
BC		105MG	N88063 001	
			SEP 10, 1982	

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

BC	GRAHAM DM	105MG	N88111 001	OCT 18, 1982
@		105MG	N87214 001	MAY 26, 1982
@		105MG	N88020 001	AUG 16, 1982
@		105MG	N88028 001	AUG 16, 1982
@		105MG	N88062 001	SEP 13, 1982
@		105MG	N88063 001	SEP 10, 1982
@		105MG	N88111 001	OCT 18, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	35MG	N84740 001	
AA		35MG	N84741 001	
AA		35MG	N84742 001	
AA		35MG	N84743 001	
@		35MG	N84740 001	
@		35MG	N84741 001	
@		35MG	N84742 001	
@		35MG	N84743 001	
AA	KV PHARM	35MG	N84138 001	
> DLT > AA		35MG	N84141 001	
AA		35MG	N85525 001	
@		35MG	N84138 001	
> ADD > @		35MG	N84141 001	
@		35MG	N85525 001	
@	ZENITH GOLDLINE	35MG	N83682 001	
@		35MG	N85611 001	
@		35MG	N85612 001	
@	ZENITH LABS	35MG	N83682 001	
@		35MG	N85611 001	
@		35MG	N85612 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	30MG	N40227 001	JUN 18, 1997

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	37.5MG	N40228 001	JUN 19, 1997
AA	KING PHARMS	30MG	N40083 001	MAR 07, 1997
@	ZENITH GOLDLINE	30MG	N86329 001	
@	ZENITH LABS	30MG	N86329 001	

TABLET; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	37.5MG	N40190 001	MAY 30, 1997
@	ECN	8MG	N85689 001	
@		8MG	N85689 001	
@	ZENITH GOLDLINE	8MG	N85553 001	
@	ZENITH LABS	8MG	N85553 001	

PHENYLBUTAZONE

CAPSULE; ORAL
PHENYLBUTAZONE

@	ZENITH GOLDLINE	100MG	N88218 001	JUN 24, 1983
@	ZENITH LABS	100MG	N88218 001	JUN 24, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP	ABBOTT	50MG/ML	N89744 001	DEC 18, 1987
AP	WINTHROP	50MG/ML	N89744 001	DEC 18, 1987

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001	
+		30MG	N84349 001	

PIMOZIDE

TABLET; ORAL
ORAP

	TEVA	1MG	N17473 003 AUG 27, 1997

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	LEMMON	**5MG**	**N74123 001** APR 17, 1997
AB		**10MG**	**N74123 002** APR 17, 1997
AB	TEVA	**5MG**	**N74123 001** APR 17, 1997
AB		**10MG**	**N74123 002** APR 17, 1997

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	EGIS	**10MG**	**N74808 001** JUL 08, 1997
AB		**20MG**	**N74808 002** JUL 08, 1997

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001 MAR 13, 1997

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT +	ALLERGAN	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N50567 001** OCT 20, 1988

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64120 001** FEB 14, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP +	ABBOTT	**745MG/100ML**	**N20161 001** NOV 30, 1992
AP +		**14.9MG/ML**	**N20161 005** NOV 30, 1992
@		745MG/100ML	N20161 001 NOV 30, 1992
@		14.9MG/ML	N20161 005 NOV 30, 1992
AP +	BAXTER HLTHCARE	**746MG/100ML**	**N19904 005** DEC 17, 1990
AP +		**14.9MG/ML**	**N19904 001** DEC 26, 1989
+		746MG/100ML	N19904 005 DEC 17, 1990
+		14.9MG/ML	N19904 001 DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP +	ABBOTT	**1.49GM/100ML**	**N20161 002** NOV 30, 1992
@		1.49GM/100ML	N20161 002 NOV 30, 1992
AP +	BAXTER HLTHCARE	**1.49GM/100ML**	**N19904 006** DEC 17, 1990
+		1.49GM/100ML	N19904 006 DEC 17, 1990

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

	MISSION PHARMA	5MEQ	N19071 001 AUG 30, 1985
+		10MEQ	N19071 002 AUG 31, 1992

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

	UNIV TX	5MEQ	N19071 001 AUG 30, 1985
+		10MEQ	N19071 002 AUG 31, 1992

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX

+	PHARMACIA AND UPJOHN	0.125MG	N20667 001 JUL 01, 1997
		0.25MG	N20667 002 JUL 01, 1997
		1MG	N20667 003 JUL 01, 1997
@		1.25MG	N20667 004 JUL 01, 1997
+		1.5MG	N20667 005 JUL 01, 1997

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX	PUREPAC PHARM	5MG	N80325 001
@		5MG	N80325 001
@	ZENITH GOLDLINE	5MG	N80378 001
BX	ZENITH LABS	5MG	N80378 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	STERIS	25MG/ML	N83654 001
@		25MG/ML	N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

+	FISONS	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

+	MEDEVA	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	HALSEY	5MG	N80300 001
@		5MG	N80300 001
@	ZENITH GOLDLINE	5MG	N80283 001
@		10MG	N84133 001
@		20MG	N84134 001
BX	ZENITH LABS	5MG	N80283 001
BX		10MG	N84133 001
@		20MG	N84134 001

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP	ABBOTT	500MG/ML	N89537 001 AUG 25, 1987
AP	WINTHROP	500MG/ML	N89537 001 AUG 25, 1987

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB	INWOOD LABS	500MG	N89840 001 MAR 06, 1989
@		500MG	N89840 001 MAR 06, 1989

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVOCAIN

AP	+	ABBOTT	1%	N85362 003
AP	+		2%	N85362 004
	+		10%	N86797 001
AP	+	STERLING WINTHROP	1%	N85362 003
AP	+		2%	N85362 004
	+		10%	N86797 001

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HCL

AP	STERIS	1%	N83535 001
AP		2%	N83535 002
@		1%	N83535 001
@		2%	N83535 002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TETRACYN

+	PFIZER	40MG/VIAL;250MG/VIAL	N60285 003
@		40MG/VIAL;250MG/VIAL	N60285 003

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	ABBOTT	EQ 5MG BASE/ML	N89703 001 APR 07, 1988
AP	STERIS	EQ 5MG BASE/ML	N89605 001 JUL 08, 1987
@		EQ 5MG BASE/ML	N89605 001 JUL 08, 1987
AP	STERLING WINTHROP	EQ 5MG BASE/ML	N89703 001 APR 07, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	DURAMED	EQ 5MG BASE	N40207 001 MAY 01, 1997
AB		EQ 10MG BASE	N40207 002 MAY 01, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

	COLUMBIA RES LABS	4%	N20701 001 JUL 31, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

+	COLUMBIA RES LABS	8%	N20701 002 JUL 31, 1997
+		8%	N20756 001 MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	ABBOTT	50MG/ML	N83838 002
AP	STERIS	25MG/ML	N83532 001
AP		50MG/ML	N83532 002
@		25MG/ML	N83532 001
@		50MG/ML	N83532 002
AP	STERLING WINTHROP	50MG/ML	N83838 002

TABLET; ORAL
PROMETHAZINE HCL

@	ZENITH GOLDLINE	12.5MG	N83604 001
@		25MG	N83603 001
@		50MG	N83613 001
BP	ZENITH LABS	12.5MG	N83604 001
BP		25MG	N83603 001
@		50MG	N83613 001

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	PAR PHARM	15MG	N88377 001 DEC 08, 1983
@		15MG	N88377 001 DEC 08, 1983

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	ROXANE	32MG	N83089 001
AA		65MG	N83089 002
@		32MG	N83089 001
@		65MG	N83089 002

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

	@ ZENITH GOLDLINE	32MG	N83597 001
AA	ZENITH LABS	**32MG**	**N83597 001**

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ROXANE	**10MG**	**N70516 001** JUL 07, 1986
AB		**20MG**	**N70517 001** JUL 07, 1986
AB		**40MG**	**N70518 001** JUL 07, 1986
AB		**60MG**	**N70519 001** SEP 24, 1986
AB		**80MG**	**N70520 001** JUL 07, 1986
AB		**90MG**	**N70521 001** SEP 24, 1986
	@	10MG	N70516 001 JUL 07, 1986
	@	20MG	N70517 001 JUL 07, 1986
	@	40MG	N70518 001 JUL 07, 1986
	@	60MG	N70519 001 SEP 24, 1986
	@	80MG	N70520 001 JUL 07, 1986
	@	90MG	N70521 001 SEP 24, 1986
	@ ZENITH GOLDLINE	10MG	N72063 001 JUL 29, 1988
	@	20MG	N72066 001 JUL 29, 1988
	@	40MG	N72067 001 JUL 29, 1988
	@	60MG	N72068 001 JUL 29, 1988
	@	80MG	N72069 001 JUL 29, 1988
AB	ZENITH LABS	**10MG**	**N72063 001** JUL 29, 1988

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ZENITH LABS	**20MG**	**N72066 001** JUL 29, 1988
AB		**40MG**	**N72067 001** JUL 29, 1988
AB		**80MG**	**N72069 001** JUL 29, 1988
	@	60MG	N72068 001 JUL 29, 1988

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

	@ ZENITH GOLDLINE	50MG	N80215 001
	@ ZENITH LABS	50MG	N80215 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL

	@ ZENITH GOLDLINE	60MG;2.5MG	N85273 001 DEC 12, 1984
AA	ZENITH LABS	**60MG;2.5MG**	**N85273 001** DEC 12, 1984

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

AP	+ ICN	**5MG/ML**	**N09830 001**
AP	+ ROCHE	**5MG/ML**	**N09830 001**

SYRUP; ORAL
MESTINON

	+ ICN	60MG/5ML	N15193 001
	+ ROCHE	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

	+ ICN	60MG	N09829 002
	+ ROCHE	60MG	N09829 002

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE; ORAL

	MESTINON			
+	ICN	180MG		N11665 001
+	ROCHE	180MG		N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PYRIDOXINE HCL			
AP	STERIS	100MG/ML		N83760 001
@		100MG/ML		N83760 001

QUETIAPINE FUMARATE

TABLET; ORAL

	SEROQUEL			
	ZENECA	EQ 25MG BASE		N20639 001 SEP 26, 1997
		EQ 100MG BASE		N20639 002 SEP 26, 1997
+		EQ 200MG BASE		N20639 003 SEP 26, 1997

QUINIDINE SULFATE

CAPSULE; ORAL

	CIN-QUIN			
	SOLVAY	200MG		N85296 001
+		300MG		N85297 001
@		200MG		N85296 001
@		300MG		N85297 001

TABLET; ORAL

	CIN-QUIN			
@	SOLVAY	100MG		N85299 001
@		200MG		N84932 001
@		300MG		N85298 001
@		100MG		N85299 001
@		200MG		N84932 001
@		300MG		N85298 001
	QUINIDINE SULFATE			
@	ZENITH GOLDLINE	200MG		N84549 001
AB	ZENITH LABS	200MG		N84549 001

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	QUINIDEX			
AB +	ROBINS AH	300MG		N12796 002
AB +	WYETH AYERST	300MG		N12796 002

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

	RANITIDINE HCL			
AB	GENEVA PHARMS	EQ 150MG BASE		N74655 001 OCT 22, 1997
AB		EQ 300MG BASE		N74655 002 OCT 22, 1997
	ZANTAC 150			
AB	GLAXO WELLCOME	EQ 150MG BASE		N20095 001 MAR 08, 1994
	ZANTAC 300			
AB +	GLAXO WELLCOME	EQ 300MG BASE		N20095 002 MAR 08, 1994

TABLET; ORAL

	RANITIDINE HCL			
AB	BOEHRINGER INGELHEIM	EQ 150MG BASE		N74662 001 AUG 29, 1997
AB		EQ 300MG BASE		N74662 002 AUG 29, 1997
AB	CHELSEA LABS	EQ 150MG BASE		N74864 001 OCT 20, 1997
AB		EQ 300MG BASE		N74864 002 OCT 20, 1997
AB	GENEVA PHARMS	EQ 150MG BASE		N74467 001 AUG 29, 1997
AB		EQ 300MG BASE		N74467 002 AUG 29, 1997
AB	GENPHARM	EQ 150MG BASE		N74023 001 AUG 22, 1997
AB		EQ 300MG BASE		N74023 002 AUG 22, 1997
AB	GRANUTEC PHARMS	EQ 150MG BASE		N74488 001 JUL 31, 1997
AB		EQ 300MG BASE		N74488 002 JUL 31, 1997
AB	TORPHARM	EQ 150MG BASE		N74680 001 SEP 12, 1997
AB		EQ 300MG BASE		N74680 002 SEP 12, 1997

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

		ZANTAC 150			
AB		GLAXO WELLCOME	EQ 150MG BASE	N18703 001	
				JUN 09, 1983	
		ZANTAC 300			
AB	+	GLAXO WELLCOME	EQ 300MG BASE	N18703 002	
				DEC 09, 1985	

RAUWOLFIA SERPENTINA

TABLET; ORAL

		RAUVAL			
> DLT >	BP	PAL PAK	50MG	N09108 002	
> DLT >		+	100MG	N09108 004	
> DLT >		@	50MG	N09108 002	
> ADD >		@	100MG	N09108 004	
> ADD >					
		RAUWOLFIA SERPENTINA			
> DLT >	BP	DANBURY PHARMA	50MG	N80907 001	
> ADD >			50MG	N80907 001	
	BP	GLOBAL PHARM	50MG	N09273 001	
	BP		100MG	N09273 002	
		@	50MG	N09273 001	
		@	100MG	N09273 002	
		@ ZENITH GOLDLINE	50MG	N11521 001	
		@	100MG	N11521 002	
		@ ZENITH LABS	50MG	N11521 001	
		@	100MG	N11521 002	

RESERPINE

TABLET; ORAL

		RESERPINE			
BP		PUREPAC PHARM	0.1MG	N80753 002	
BP			0.25MG	N80753 001	
		@	0.1MG	N80753 002	
		@	0.25MG	N80753 001	
		@ TABLICAPS	0.25MG	N85207 001	
		@	0.25MG	N85207 001	
		@ ZENITH GOLDLINE	0.1MG	N11185 001	
		@	0.25MG	N11185 002	> ADD >
		@ ZENITH LABS	0.1MG	N11185 001	> ADD >
		@	0.25MG	N11185 002	> ADD >

RIFAMPIN

CAPSULE; ORAL

		RIFAMPIN		
AB		EON	300MG	N64150 001
				MAY 28, 1997

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

	REQUIP		
	+ SMITHKLINE BEECHAM	EQ 0.25MG BASE	N20658 001
			SEP 19, 1997
		EQ 0.5MG BASE	N20658 002
			SEP 19, 1997
		EQ 1MG BASE	N20658 003
			SEP 19, 1997
		EQ 2MG BASE	N20658 004
			SEP 19, 1997
	+	EQ 5MG BASE	N20658 005
			SEP 19, 1997

SALMETEROL XINAFOATE

POWDER; INHALATION

	SEREVENT		
	+ GLAXO WELLCOME	EQ 0.046MG BASE/INH	N20692 001
			SEP 19, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

	QUADRAMET		
	CYTOGEN	50mCi/ML	N20570 001
			MAR 28, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL

	FORTOVASE		
	ROCHE	EQ 200MG BASE	N20828 001
			NOV 07, 1997

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

		TRANSDERM SCOP			
>DLT>	+	CIBA	0.5MG/24HR	N17874 001	
>ADD>	+	NOVARTIS	1MG/72HR	N17874 001	

SECOBARBITAL SODIUM

CAPSULE; ORAL

		SECOBARBITAL SODIUM			
	@	ZENITH GOLDLINE	100MG	N85869 001	
	@	ZENITH LABS	100MG	N85869 001	
		SODIUM SECOBARBITAL			
AA		**HALSEY**	**100MG**	**N84676 001**	
	@		100MG	N84676 001	

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

		ELDEPRYL			
AB	+	SOMERSET	**5MG**	**N20647 001**	
				MAY 15, 1996	
	+		5MG	N20647 001	
				MAY 15, 1996	

TABLET; ORAL

		SELEGILINE HCL			
>ADD>	**AB**	ALPHAPHARM	**5MG**	**N74866 001**	
>ADD>				NOV 26, 1997	
	AB	APOTEX	**5MG**	**N74871 001**	
				JUN 06, 1997	
	AB	APOTHECON	**5MG**	**N74672 001**	
				APR 01, 1997	
	AB	ENDO LABS	**5MG**	**N74565 001**	
				AUG 02, 1996	
	AB	ENDO PHARMS	**5MG**	**N74565 001**	
				AUG 02, 1996	
	AB	TEVA	**5MG**	**N74744 001**	
				JAN 27, 1997	

SERMORELIN ACETATE

INJECTABLE; INJECTION

		GEREF			
	+	SERONO	EQ 0.5MG BASE/VIAL	N20443 001	
				SEP 26, 1997	

SERMORELIN ACETATE

INJECTABLE; INJECTION

		GEREF			
	+	SERONO	EQ 1MG BASE/VIAL	N20443 002	
				SEP 26, 1997	

>ADD> SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

>ADD>		MERIDIA			
>ADD>		KNOLL PHARM	5MG	N20632 001	
>ADD>				NOV 22, 1997	
>ADD>			10MG	N20632 002	
>ADD>				NOV 22, 1997	
>ADD>	+		15MG	N20632 003	
>ADD>				NOV 22, 1997	

SODIUM CHLORIDE

INJECTABLE; INJECTION

		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP		ABBOTT	**9MG/ML**	**N19465 002**	
				JUL 15, 1985	

SODIUM IODIDE, I-123

CAPSULE; ORAL

		SODIUM IODIDE I 123			
AA		GOLDEN PHARMS	**100 uCi**	**N18671 001**	
				MAY 27, 1982	
AA			**200 uCi**	**N18671 002**	
				MAY 27, 1982	
	@		400 uCi	N18671 003	
				MAY 27, 1982	
>DLT>	**AA**	MEDI PHYSICS	**100 uCi**	**N17630 001**	
>ADD>	**AA**	NYCOMED AMERSHAM	**100 uCi**	**N17630 001**	
	AA	SYNCOR PHARMS	**100 uCi**	**N18671 001**	
				MAY 27, 1982	
	AA		**200 uCi**	**N18671 002**	
				MAY 27, 1982	
	@		400 uCi	N18671 003	
				MAY 27, 1982	

SODIUM IODIDE, I-131

CAPSULE; ORAL

	IODOTOPE			
	BRACCO	8-100 uCi	N10929 001	
		1-50mCi	N10929 003	
	@	8-100 uCi	N10929 001	
		1-130mCi	N10929 003	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

	NITROPRESS			
AP	ABBOTT	50MG/VIAL	N71555 001 NOV 16, 1987	> DLT >
	@	50MG/VIAL	N71555 001 NOV 16, 1987	> DLT >
				> ADD >
				> ADD >

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

	NORDITROPIN		
BX +	NOVO NORDISK	4MG/VIAL	N19721 001 MAY 08, 1995
	SEROSTIM		
BX	SERONO	4MG/VIAL	N20604 003 JUL 25, 1997

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE			
	BERLEX	80MG	N19865 001 OCT 30, 1992	> DLT >
+		240MG	N19865 003 OCT 30, 1992	> DLT >
+	BERLEX LABS	80MG	N19865 001 OCT 30, 1992	> DLT >
		240MG	N19865 003 OCT 30, 1992	> ADD >
				> ADD >
				> ADD >

SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE		
@	ZENITH GOLDLINE	25MG	N87108 001

SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE		
AB	ZENITH LABS	25MG	N87108 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

	METASTRON			
	MEDI PHYSICS	1mCi/ML	N20134 001 JUN 18, 1993	> DLT >
	NYCOMED AMERSHAM	1mCi/ML	N20134 001 JUN 18, 1993	> DLT >
				> ADD >
				> ADD >

SULFAMETHOXAZOLE

SUSPENSION; ORAL

	GANTANOL		
+	ROCHE	500MG/5ML	N13664 002
@		500MG/5ML	N13664 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AP	ABBOTT	80MG/ML;16MG/ML	N73199 001 SEP 11, 1992
AP	STERLING WINTHROP	80MG/ML;16MG/ML	N73199 001 SEP 11, 1992

SULFINPYRAZONE

CAPSULE; ORAL

	SULFINPYRAZONE		
AB	ZENITH GOLDLINE	200MG	N87770 001 NOV 19, 1982
AB	ZENITH LABS	200MG	N87770 001 NOV 19, 1982

TABLET; ORAL

	SULFINPYRAZONE		
@	ZENITH GOLDLINE	100MG	N87769 001 JUN 01, 1982

SULFINPYRAZONE

TABLET; ORAL
SULFINPYRAZONE
AB ZENITH LABS 100MG N87769 001 JUN 01, 1982

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
AB PUREPAC PHARM 500MG N80087 001
@ 500MG N80087 001
AB + ZENITH GOLDLINE 500MG N80142 001
AB + ZENITH LABS 500MG N80142 001

SULFISOXAZOLE DIOLAMINE

SOLUTION/DROPS; OPHTHALMIC
GANTRISIN
+ ROCHE EQ 4% BASE N07757 002
@ EQ 4% BASE N07757 002

SUMATRIPTAN

SPRAY; NASAL
IMITREX
+ GLAXO WELLCOME 5MG/SPRAY N20626 001 AUG 26, 1997 >DLT> >ADD>
+ 10MG/SPRAY N20626 002 AUG 26, 1997
+ 20MG/SPRAY N20626 003 AUG 26, 1997

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ZENECA EQ 10MG BASE N17970 001 >DLT> >DLT> >ADD> >ADD>
EQ 10MG BASE N17970 001

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
+ BOEHRINGER INGELHEIM 0.4MG N20579 001 APR 15, 1997

TAZAROTENE

GEL; TOPICAL
TAZORAC
ALLERGAN 0.05% N20600 001 JUN 13, 1997
+ 0.1% N20600 002 JUN 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
AN-MAA
@ CIS N/A N17792 001
BS SORIN N/A N17792 001

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M HSA
MEDI PHYSICS N/A N17775 001
NYCOMED AMERSHAM N/A N17775 001

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC
AMERSHAM N/A N19829 001 DEC 30, 1988
NYCOMED AMERSHAM N/A N19829 001 DEC 30, 1988

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-BRACCO
AP BRACCO N/A N18107 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-SQUIBB

	AP	BRACCO	N/A	N18107 001	

TECHNETIUM TC 99M MPI MDP

> DLT >	AP	MEDI PHYSICS	N/A	N18141 001	
> ADD >	AP	NYCOMED AMERSHAM	N/A	N18141 001	

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
MPI DTPA KIT - CHELATE

> DLT >	AP	MEDI PHYSICS	N/A	N17255 001	
> ADD >	AP	NYCOMED AMERSHAM	N/A	N17255 001	

TECHNETIUM TC-99M PENTETATE KIT

> DLT >	AP	MEDI PHYSICS	N/A	N17264 002	
> ADD >	AP	NYCOMED AMERSHAM	N/A	N17264 002	

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
MIRALUMA

		DUPONT	N/A	N19785 003	MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M GENERATOR

> DLT >	MEDI PHYSICS	830-16,600mCi/GENERATOR	N17693 001	
> ADD >	NYCOMED AMERSHAM	830-16,600mCi/GENERATOR	N17693 001	

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT

> DLT >	MEDI PHYSICS	N/A	N17944 001	MAY 18, 1982
> DLT >				
> ADD >	NYCOMED AMERSHAM	N/A	N17944 001	MAY 18, 1982
> ADD >				

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW

> DLT >	MEDI PHYSICS	N/A	N20372 001	FEB 09, 1996
> DLT >				
> ADD >	NYCOMED AMERSHAM	N/A	N20372 001	FEB 09, 1996
> ADD >				

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL
LAMISIL

+	NOVARTIS	1%	N20749 001	OCT 17, 1997

TERFENADINE

TABLET; ORAL
SELDANE

AB	+	HOECHST MARION RSSL	60MG	N18949 001	MAY 08, 1985

TERFENADINE

AB		BAKER NORTON	60MG	N74475 001	JAN 03, 1997

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

+	THERATECH	5MG/24HR	N20489 002	MAY 02, 1997

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	WARNER CHILCOTT	250MG	N62300 001	
AB		500MG	N62300 002	
@		250MG	N62300 001	
@		500MG	N62300 002	

INJECTABLE; INJECTION
ACHROMYCIN

AP	+ LEDERLE	250MG/VIAL	N50273 002	

TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ACHROMYCIN			
AP	LEDERLE	500MG/VIAL	N50273 003	
	+	250MG/VIAL	N50273 002	
		500MG/VIAL	N50273 003	
	TETRACYN			
AP	PFIZER	250MG/VIAL	N60096 001	
AP		500MG/VIAL	N60096 002	
	@	250MG/VIAL	N60096 001	
	@	500MG/VIAL	N60096 002	

SUSPENSION; ORAL

	TETRACYCLINE HCL			
AB	ALPHARMA	125MG/5ML	N60633 001	
	@	125MG/5ML	N60633 001	
AB	PUREPAC PHARM	125MG/5ML	N60291 001	
	@	125MG/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	125MG/5ML	N60095 001	
	@	125MG/5ML	N60095 001	
	TETRAMED			
	@ ZENITH GOLDLINE	125MG/5ML	N61468 001	
AB	ZENITH LABS	125MG/5ML	N61468 001	

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

	THALLOUS CHLORIDE TL 201			
AP	DUPONT	1mCi/ML	N17806 001	
AP	+	1mCi/ML	N17806 001	
AP	MALLINCKRODT	1mCi/ML	N18150 001	
AP	+	1mCi/ML	N18150 001	
> DLT > AP	+ MEDI PHYSICS	1mCi/ML	N18110 002	FEB 27, 1996
> DLT >				
> ADD > AP	+ NYCOMED AMERSHAM	1mCi/ML	N18110 002	FEB 27, 1996
> ADD >				

THEOPHYLLINE

CAPSULE; ORAL

	BRONKODYL			
BP	STERLING WINTHROP	100MG	N85264 001	
BP		200MG	N85264 002	
	@	100MG	N85264 001	
	@	200MG	N85264 002	

THEOPHYLLINE

CAPSULE; ORAL

	THEOPHYLLINE			
BP	KV PHARM	100MG	N85263 001	
BP		200MG	N85263 002	
	@	100MG	N85263 001	
	@	200MG	N85263 002	

CAPSULE, EXTENDED RELEASE; ORAL

	SOMOPHYLLIN-CRT			
BC	GRAHAM DM	50MG	N87763 001	
BC		100MG	N87763 001	FEB 27, 1985
BC		200MG	N87194 001	
BC		250MG	N88382 001	
BC		300MG	N88382 001	FEB 27, 1985
	@	50MG	N87193 001	
	@	100MG	N87763 001	FEB 27, 1985
	@	200MG	N87194 001	
	@	250MG	N88383 001	
	@	300MG	N88382 001	FEB 27, 1985
			N87193 001	
			N88383 001	FEB 27, 1985
	THEO-DUR			
BC	KEY PHARMS	50MG	N88022 001	
BC		75MG	N88022 001	SEP 10, 1985
BC		125MG	N88015 001	
BC		200MG	N88015 001	SEP 10, 1985
	@ SCHERING	50MG	N88016 001	
	@	75MG	N88016 001	SEP 10, 1985
	@	125MG	N87995 001	
	@	200MG	N87995 001	SEP 10, 1985
			N88022 001	
			N88022 001	SEP 10, 1985
			N88015 001	
			N88015 001	SEP 10, 1985
			N88016 001	
			N88016 001	SEP 10, 1985
			N87995 001	
			N87995 001	SEP 10, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

AP	ABBOTT	100MG/ML	N40079 001 MAY 03, 1996
AP	SANOFI WINTHROP	100MG/ML	N40079 001 MAY 03, 1996
AP	STERIS	100MG/ML	N83534 001
		200MG/ML	N83534 002
@		100MG/ML	N83534 001
@		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	PHARM ASSOC	30MG/ML	N40187 001 AUG 28, 1997

THYROTROPIN

INJECTABLE; INJECTION
THYTROPAR

+	ARMOUR PHARM	10 IU/VIAL	N08682 001
@	RHONE POULENC	10 IU/VIAL	N08682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL
ABBOTT

		4MG	N20646 001 SEP 30, 1997
		12MG	N20646 002 SEP 30, 1997
		16MG	N20646 003 SEP 30, 1997
+		20MG	N20646 004 SEP 30, 1997

TILUDRONATE DISODIUM

TABLET; ORAL
SKELID

+	SANOFI	EQ 200MG BASE	N20707 001 MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL

+	LEIRAS	EQ 0.25% BASE	N20439 001 MAR 31, 1995
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995
+	OY STAR	EQ 0.25% BASE	N20439 001 MAR 31, 1995
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	ADV REMEDIES	EQ 0.25% BASE	N74465 001 MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001 MAR 25, 1997
AT	AKORN	EQ 0.25% BASE	N74515 001 MAR 25, 1997
AT		EQ 0.5% BASE	N74516 001 MAR 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001 MAR 25, 1997
AT		EQ 0.5% BASE	N74776 001 MAR 25, 1997
AT	FOUGERA	EQ 0.25% BASE	N74667 001 MAR 25, 1997
AT		EQ 0.5% BASE	N74668 001 MAR 25, 1997
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001 MAR 25, 1997
AT		EQ 0.5% BASE	N74747 001 MAR 25, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986

TIOPRONIN

TABLET; ORAL
TIOPRONIN
+ MISSION PHARMA 100MG N19569 001 AUG 11, 1988
+ UNIV TX 100MG N19569 001 AUG 11, 1988

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
AB PUREPAC PHARM 500MG N88950 001 JUN 17, 1985
@ 500MG N88950 001 JUN 17, 1985

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM
AB BAKER NORTON EQ 600MG BASE N74399 001 MAR 28, 1996
AB LEMMON EQ 600MG BASE N74729 001 FEB 27, 1997
@ TEVA EQ 600MG BASE N74729 001 FEB 27, 1997
AB ZENITH GOLDLINE EQ 600MG BASE N74399 001 MAR 28, 1996

TOPIRAMATE

TABLET; ORAL
TOPAMAX
@ JOHNSON RW 400MG N20505 006 DEC 24, 1996

> ADD >
> ADD >

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON
+ ORION EQ 60MG BASE N20497 001 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
AB TEVA 150MG N74357 001 APR 30, 1997

TRETINOIN

CREAM; TOPICAL
AVITA
AB PENEDERM 0.025% N20404 003 JAN 14, 1997

RETIN-A
AB + J AND J 0.025% N19049 001 SEP 16, 1988

GEL; TOPICAL
RETIN-A MICRO
+ ADV POLYMER 0.1% N20475 001 FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE
BP PUREPAC PHARM 2MG N84020 002
BP 4MG N84020 003
@ 2MG N84020 002
@ 4MG N84020 003
@ ZENITH GOLDLINE 4MG N83750 001
BP ZENITH LABS 4MG N83750 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
AT TARO 0.1% N40039 001 NOV 26, 1997

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE
AT ALPHARMA 0.1% N87192 001 SEP 08, 1982
@ 0.1% N87192 001 SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

BP	STERIS	40MG/ML		N85529 001
	@	40MG/ML		N85529 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	MYLAN	**EQ 1MG BASE**		**N40209 001** **JUL 07, 1997**
AB		**EQ 2MG BASE**		**N40209 002** **JUL 07, 1997**
AB		**EQ 5MG BASE**		**N40209 003** **JUL 07, 1997**
AB		**EQ 10MG BASE**		**N40209 004** **JUL 07, 1997**

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE

+	LEDERLE	5MG		N12947 001
	@	5MG		N12947 001

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL

AA	PHARM ASSOC	**2MG/5ML**		**N40177 001** APR 17, 1997

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

AP	ABBOTT	**100MG/ML**		**N88804 001** APR 03, 1987
AP	STERLING WINTHROP	**100MG/ML**		**N88804 001** APR 03, 1987

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

AB	GLAXO WELLCOME	**200MG**		**N17943 003** JUL 14, 1982
AB	+	**200MG**		**N17943 003** JUL 14, 1982

TRIMPEX 200

AB	+ ROCHE	**200MG**		**N17952 002** NOV 09, 1982
	@	200MG		N17952 002 NOV 09, 1982

TROGLITAZONE

TABLET; ORAL
PRELAY

AB	SANKYO	**200MG**		**N20719 001** JAN 29, 1997
AB		**300MG**		**N20719 003** AUG 04, 1997
AB		**400MG**		**N20719 002** JAN 29, 1997

REZULIN

AB	PARKE DAVIS	**200MG**		**N20720 001** JAN 29, 1997
AB		**300MG**		**N20720 003** AUG 04, 1997
AB		**400MG**		**N20720 002** JAN 29, 1997

UREA, C-14

CAPSULE; ORAL
PYTEST

+	TRI MED SPECLTS	1 uCi		N20617 001 MAY 09, 1997

PYTEST KIT

+	TRI MED SPECLTS	1 uCi		N20617 002 MAY 09, 1997

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LYPHOCIN

> DLT >	AP	FUJISAWA	EQ 500MG BASE/VIAL	N62663 001 MAR 17, 1987
> DLT >	AP		EQ 1GM BASE/VIAL	N62663 002 JUL 31, 1987
> DLT >	AP		EQ 5GM BASE/VIAL	N62663 003 JUN 03, 1988

VANCOCIN HCL IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993
+	LILLY	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993

VANCOLED

	AP	LEDERLE	EQ 500MG BASE/VIAL	N62682 001 JUL 22, 1986
	AP	+	EQ 500MG BASE/VIAL	N62682 001 JUL 22, 1986
	AP		EQ 1GM BASE/VIAL	N62682 002 MAR 30, 1988
	AP	+	EQ 1GM BASE/VIAL	N62682 002 MAR 30, 1988
	AP		EQ 10GM BASE/VIAL	N62682 005 MAY 11, 1988
	AP	+	EQ 10GM BASE/VIAL	N62682 005 MAY 11, 1988

VANCOMYCIN HCL

> ADD >	AP	FUJISAWA	EQ 500MG BASE/VIAL	N62663 001 MAR 17, 1987
> ADD >	AP		EQ 1GM BASE/VIAL	N62663 002 JUL 31, 1987
> ADD >	AP		EQ 5GM BASE/VIAL	N62663 003 JUN 03, 1988
> ADD >	AP		EQ 10GM BASE/VIAL	N62663 004 NOV 28, 1997

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

+	WYETH AYERST	EQ 37.5MG BASE	N20699 001 OCT 20, 1997
+		EQ 75MG BASE	N20699 002 OCT 20, 1997
@		EQ 100MG BASE	N20699 003 OCT 20, 1997

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

+	WYETH AYERST	EQ 150MG BASE	N20699 004 OCT 20, 1997

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	ABBOTT	2.5MG/ML	N70577 001 FEB 02, 1987
AP	STERLING WINTHROP	2.5MG/ML	N70577 001 FEB 02, 1987

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

AB	+ KNOLL PHARM	120MG	N19152 003 MAR 06, 1991

VERAPAMIL HCL

AB	BAKER NORTON	180MG	N74330 001 JAN 31, 1994
AB		240MG	N73568 001 JUL 31, 1992
AB	MYLAN	120MG	N74587 002 FEB 21, 1997
AB		180MG	N74587 003 SEP 09, 1997
AB	ZENITH GOLDLINE	120MG	N73568 002 OCT 10, 1997
AB		180MG	N74330 001 JAN 31, 1994
AB		240MG	N73568 001 JUL 31, 1992

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCREX

AP	+ BRISTOL MYERS	5MG/VIAL	N70867 001 JUL 12, 1988
	@ BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001 JUL 12, 1988

VINCRISTINE SULFATE

AP	FAULDING	5MG/VIAL	N71561 001 APR 11, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

+	FAULDING	5MG/VIAL	N71561 001 APR 11, 1988	

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A

@	ZENITH GOLDLINE	EQ 50,000 UNITS BASE	N83035 001	
@		EQ 50,000 UNITS BASE	N83190 001	
@	ZENITH LABS	EQ 50,000 UNITS BASE	N83035 001	
@		EQ 50,000 UNITS BASE	N83190 001	

WARFARIN SODIUM

TABLET; ORAL
COUMADIN

AB	DUPONT MERCK	1MG	**N09218 022** MAR 01, 1990	
AB	+	2MG	**N09218 013**	
AB		2.5MG	**N09218 018**	
AB		4MG	**N09218 023** AUG 24, 1993	
AB		5MG	**N09218 007**	> ADD >
AB		7.5MG	**N09218 016**	
AB	+	10MG	**N09218 005**	> ADD >

WARFARIN SODIUM > ADD >

AB	BARR	1MG	**N40145 001** MAR 26, 1997	> ADD >
AB		2MG	**N40145 002** MAR 26, 1997	> ADD >
AB		2.5MG	**N40145 003** MAR 26, 1997	
AB		4MG	**N40145 004** MAR 26, 1997	
AB		5MG	**N40145 005** MAR 26, 1997	
AB		7.5MG	**N40145 006** MAR 26, 1997	
AB		10MG	**N40145 007** MAR 26, 1997	
AB	INVAMED	1MG	**N40196 001** SEP 30, 1997	

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

AB	INVAMED	2MG	**N40196 002** SEP 30, 1997	
AB		2.5MG	**N40196 003** SEP 30, 1997	
AB		4MG	**N40196 004** SEP 30, 1997	
AB		5MG	**N40196 005** SEP 30, 1997	
AB		7.5MG	**N40196 006** SEP 30, 1997	
AB		10MG	**N40196 007** SEP 30, 1997	

ZINC ACETATE

CAPSULE; ORAL
GALZIN

	TEVA	EQ 25MG ZINC	N20458 001 JAN 28, 1997	
+		EQ 50MG ZINC	N20458 002 JAN 28, 1997	

ZOLMITRIPTAN

TABLET; ORAL
ZOMIG

	ZENECA	2.5MG	N20768 001 NOV 25, 1997	
+		5MG	N20768 002 NOV 25, 1997	

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
DYNA-HEX
XTTRIUM 0.75% N20111 001 SEP 11, 1997

> DLT > TINCTURE; TOPICAL
> DLT > HIBITANE
> DLT > @ ZENECA 0.5% N18049 001

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE
GENEVA PHARMS 12MG N70797 001 AUG 12, 1988
\+ 12MG N70797 001 AUG 12, 1988
TELDRIN
\+ SMITHKLINE 12MG N17369 002
@ 12MG N17369 002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
COLD CAPSULE IV
\+ GRAHAM DM 12MG;75MG N18793 001 APR 25, 1985
@ 12MG;75MG N18793 001 APR 25, 1985
COLD CAPSULE V
GRAHAM DM 8MG;75MG N18794 001 APR 23, 1985
@ 8MG;75MG N18794 001 APR 23, 1985

TABLET, EXTENDED RELEASE; ORAL
CONTAC
NOVARTIS 12MG;75MG N19613 001 JUN 13, 1986
PHENYLPROPANOLAMINE HCL/CHLORPHENIRAMINE
SANDOZ 12MG;75MG N19613 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CODIMAL-L.A. 12
\+ CENT PHARMS 12MG;120MG N18935 001 APR 15, 1985
@ SCHWARZ PHARMA 12MG;120MG N18935 001 APR 15, 1985
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE
KV PHARM 12MG;120MG N71455 001 MAR 01, 1989
@ 12MG;120MG N71455 001 MAR 01, 1989

CIMETIDINE

TABLET; ORAL
TAGAMET HB
SMITHKLINE BEECHAM 100MG N20238 001 JUN 19, 1995
@ 100MG N20238 001 JUN 19, 1995

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE
LEMMON 1.34MG N73282 002 DEC 03, 1992
TEVA 1.34MG N73282 002 DEC 03, 1992

CLOTRIMAZOLE

CREAM; TOPICAL
LOTRIMIN AF
\+ SCHERING PLOUGH 1% N17619 002 OCT 27, 1989
\+ 1% N20888 001 OCT 27, 1989

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN 3 COMBINATION PACK
\+ SCHERING PLOUGH 1%,200MG N20526 002 JUL 29, 1996

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL				
GYNE-LOTRIMIN COMBINATION PACK				
+ SCHERING PLOUGH	1%,100MG	N20289 002 APR 26, 1993		
MYCELEX-7 COMBINATION PACK				
BAYER	1%,100MG	N20389 002 JUN 23, 1994		
CREAM, TABLET; TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ SCHERING PLOUGH	1%,200MG	N20526 002 JUL 29, 1996		
GYNE-LOTRIMIN COMBINATION PACK				
+ SCHERING PLOUGH	1%,100MG	N20289 002 APR 26, 1993		
MYCELEX-7 COMBINATION PACK				
BAYER	1%,100MG	N20389 002 JUN 23, 1994		
LOTION; TOPICAL			>DLT<	
LOTRIMIN AF			>DLT<	
+ SCHERING	1%	N18813 002 OCT 27, 1989	>DLT<	
+ SCHERING PLOUGH	1%	N20889 001 OCT 27, 1989	>DLT<	
			>ADD<	
			>ADD<	
SOLUTION; TOPICAL				
LOTRIMIN AF				
+ SCHERING PLOUGH	1%	N17613 002 OCT 27, 1989	>DLT<	
+	1%	N20890 001 OCT 27, 1989	>DLT<	
			>DLT<	
			>DLT<	
SUPPOSITORY; VAGINAL				
GYNE-LOTRIMIN				
+ SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990	>ADD<	
			>ADD<	
			>ADD<	
GYNE-LOTRIMIN 3				
+ SCHERING PLOUGH	200MG	N20525 001 JUL 29, 1996		
MYCELEX-7				
BAYER	100MG	N18182 002 DEC 26, 1991		
TABLET; VAGINAL				
GYNE-LOTRIMIN				
+ SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990		

CLOTRIMAZOLE

TABLET; VAGINAL		
GYNE-LOTRIMIN 3		
+ SCHERING PLOUGH	200MG	N20525 001 JUL 29, 1996
MYCELEX-7		
BAYER	100MG	N18182 002 DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL		
NASALCROM		
+ PHARMACIA AND UPJOHN	5.2MG/SPRAY	N20463 001 JAN 03, 1997

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL		
BENYLIN		
+ PARKE DAVIS	12.5MG/5ML;30MG/5ML	N19014 001 JUN 11, 1985
@	12.5MG/5ML;30MG/5ML	N19014 001 JUN 11, 1985

IBUPROFEN

CAPSULE; ORAL		
PROVEL		
@ SANDOZ	200MG	N20402 001 APR 20, 1995
SUSPENSION; ORAL		
CHILDREN'S ADVIL-FLAVORED		
+ WHITEHALL ROBINS	100MG/5ML	N20589 002 NOV 07, 1997
TABLET; ORAL		
IBUPROFEN		
PUREPAC PHARM	200MG	N71122 001 OCT 03, 1986
	200MG	N71664 001 FEB 03, 1987
@	200MG	N71122 001 OCT 03, 1986

IBUPROFEN

TABLET; ORAL

IBUPROFEN			
@ PUREPAC PHARM	200MG	N71664 001	FEB 03, 1987
@ ZENITH GOLDLINE	200MG	N71154 001	OCT 27, 1987
@	200MG	N72040 001	APR 29, 1988
@ ZENITH LABS	200MG	N71154 001	OCT 27, 1987
@	200MG	N72040 001	APR 29, 1988
JUNIOR STRENGTH MOTRIN			
MCNEIL	100MG	N20602 001	JUN 10, 1996
+	100MG	N20602 001	JUN 10, 1996
NUPRIN			
@ MCNEIL	200MG	N19012 001	MAY 18, 1984
@	200MG	N19012 003	JUL 29, 1987
@ PHARMACIA AND UPJOHN	200MG	N19012 001	MAY 18, 1984
@	200MG	N19012 003	JUL 29, 1987

IBUPROFEN POTASSIUM

CAPSULE; ORAL

PROVEL			
@ NOVARTIS	200MG	N20402 001	APR 20, 1995

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

VELOSULIN BR HUMAN			
+ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986
VELOSULIN HUMAN			
+ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D			
J AND J	1%	N20310 001	OCT 10, 1997

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HCL			
MORTON GROVE	1MG/5ML	N74730 001	AUG 28, 1997

TABLET, CHEWABLE; ORAL

IMODIUM A-D			
+ MCNEIL	2MG	N20448 001	JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

IMODIUM ADVANCED			
+ MCNEIL	2MG;125MG	N20606 001	JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE			
PERRIGO	2%	N74760 001	MAY 15, 1997
TARO	2%	N74444 001	JAN 13, 1997

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK			
ALPHARMA	2%,100MG	N74586 001	JUL 17, 1997

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE			
G AND W LABS	100MG	N74414 001	APR 30, 1997
+ PERRIGO	100MG	N74395 001	MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

	MORTON GROVE	2%	N74767 001 FEB 28, 1997
> ADD >	ROGAINE EXTRA STRENGTH (FOR MEN)		
> ADD >	+ PHARMACIA AND UPJOHN	5%	N20834 001 NOV 14, 1997

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

GRANUTEC	EQ 200MG BASE	N74635 001 JAN 13, 1997
INVAMED	EQ 200MG BASE	N74646 001 JAN 13, 1997
NOVOPHARM	EQ 200MG BASE	N74635 001 JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL
NIX

+	WARNER LAMBERT	1%	N19918 001 MAY 02, 1990
+	WARNER WELLCOME	1%	N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

	KV PHARM	120MG;5MG	N71798 001 MAR 16, 1989
@		120MG;5MG	N71798 001 MAR 16, 1989

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL

+	COLGATE PALMOLIVE	0.24%;0.3%	N20231 001 JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+	BRISTOL MYERS SQUIBB	6.5%	N20676 001 FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 11/ NOVEMBER '97

NO NOVEMBER 1997 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Ancrod TN=	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceuticals 30 North Jefferson Road Whippany, NJ 07981 DD=11/12/1997
Apomorphine TN= Zydis	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon Wiltshire UK SN5 8RU, DD=10/20/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997
Busulfan TN= Spartaject	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CAMPATH-1H TN=	Treatment of chronic lymphocytic leukemia.	L&I Partners, LP 11550 IH 10 West, Suite 300 San Antonio, TX 78230 DD=10/20/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Calcium gluconate TN= Calgonate	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive Warwick, RI 02886 DD=11/20/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Sreet Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Pegylated recombinant human megakaryocyte growth and development factor TN= MEGAGEN	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=10/20/1997
Pergolide TN= Permax	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Medical University of South Carolina 171 Ashley Avenue, Room PH246 Charleston, SC 29425 DD=11/20/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Purified extract of Pseudomonas aeruginosa TN= ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge, MA 02139 DD=09/22/1997
RGG0853, E1A lipid complex TN=	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive way, Suite 100 Seattle, WA 98101 DD=10/27/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human acid alpha-glucosidase TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Recombinant human alpha-L-iduronidase TN=	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceuticals, Inc. 11 Pimental Court Novato, CA 94949 DD=09/24/1997
Recombinant human interleukin-12 TN=	Treatment of renal cell carcinoma.	Genetics Institute 87 CambridgePark Drive Cambridge, MA 02140 DD=10/20/1997
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=09/29/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Sermorelin acetate TN= Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=09/14/1988 MA=09/26/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Short chain fatty acid enema TN= Colomed	Treatment of chronic radiation proctitis.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=08/19/1997
Somatropin TN= Genotropin	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=09/06/1994 MA=10/31/1997
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Testosterone TN= TheraDerm Testosterone Transdermal System	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	TheraTech, Inc. 417 Wakara Way Salt Lake City, UT 84108 DD=09/22/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997

Orphan Product Designations and Approvals List
January 1997 through November 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVE TWICE DAILY

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THNNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	USE OF LANSOPRAZOLE IN COMBINATION WITHCLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OFSTATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD OF TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
>ADD>	020760	001	ALATROFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
	020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
				5439670	JUL 06, 2010			
				5605674	FEB 25, 2014			
	020560	001	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
				5681590	DEC 02, 2012		I-187	APR 25, 2000
	020560	002	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
				5681590	DEC 02, 2012		I-187	APR 25, 2000
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
				4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
				5681590	DEC 02, 2012		I-187	APR 25, 2000
							NCE	SEP 29, 2000
	020649	001	ALPROSTADIL;EDEX				NP	JUL 06, 1998
	020649	002	ALPROSTADIL;EDEX				NP	JUL 06, 1988
	020649	003	ALPROSTADIL;EDEX				NP	JUL 06, 1998
	020649	004	ALPROSTADIL;EDEX				NP	JUL 06, 1998
	020221	001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
				5591731	JUL 31, 2012			
	020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020541	001	ANASTROZOLE;ARIMIDEX	4935437	DEC 27, 2009			
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA				NCE	SEP 12, 2002
	020227	002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
>ADD>	020702	001	ATORVASTATIN CALCIUM;LIPITOR	5686104	NOV 11, 2014	U-213	NCE	DEC 17, 2001
				4681893	MAY 30, 2006	U-161		
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
>ADD>	020702	002	ATORVASTATIN CALCIUM;LIPITOR	5686104	NOV 11, 2014	U-213	NCE	DEC 17, 2001
				4681893	MAY 30, 2006	U-161		
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
>ADD>	020702	003	ATORVASTATIN CALCIUM;LIPITOR	5686104	NOV 11, 2014	U-213	NCE	DEC 17, 2001
				4681893	MAY 30, 2006	U-161		
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 17, 2009	U-207		
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
	020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
	020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
	020498	001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
				4472382	SEP 18, 2001	U-197		
				5389613	SEP 18, 2001	U-197		
	020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
							NCE	SEP 06, 2001
	020535	002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020441	002	BUDESONIDE;PULMICORT	4907583	MAR 13, 2007			
				4524769	JUN 25, 2002			
				4668218	APR 11, 2006			
	020441	003	BUDESONIDE;PULMICORT	4907583	MAR 13, 2007			
				4524769	JUN 25, 2002			
				4668218	APR 11, 2006			
	018644	001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013			
				5427798	AUG 12, 2013		NP	MAY 14, 2000
	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	RE33994	AUG 18, 2004			
				5358970	AUG 12, 2013			
				5427798	AUG 12, 2013		NP	MAY 14, 2000
				RE33994	AUG 18, 2004			
	018731	003	BUSPIRONE HYDROCHLORIDE;BUSPAR	4215104	MAR 26, 1999			
				4258027	MAR 26, 1999			
	018731	004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4215104	MAR 26, 1999			
				4258027	MAR 26, 1999			
>ADD>	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177	D-35	NOV 25, 2000
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664	001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NCE	DEC 29, 1998
							NDF	MAR 03, 2000
	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	020297	001	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	002	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	003	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020297	004	CARVEDILOL;COREG				I-194	MAY 29, 2000
				4503067	MAR 05, 2002	U-3	NCE	SEP 14, 2000
	020740	001	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
				5177080	NOV 26, 2011			
	020740	002	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
				5177080	NOV 26, 2011			
	020740	003	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
				5177080	NOV 26, 2011			
	020740	004	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
				5177080	NOV 26, 2011			
	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020519	001	CICLOPIROX;LOPROX					
	019537	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011		NDF	JUL 21, 2000
				4670444	DEC 09, 2003	U-36	I-188	JUN 03, 2000
	019537	002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019537	003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019537	004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019847	001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
							I-201	AUG 07, 2000
>ADD>	020780	001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
>ADD>	020780	002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
							I-201	AUG 07, 2000
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
							I-201	AUG 07, 2000
>ADD>	020767	001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	017533	001	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
>ADD>	020813	001	CLONAZEPAM;KLONOPIN	4305502	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>				4758598	DEC 15, 1998			
>ADD>	020813	002	CLONAZEPAM;KLONOPIN	4305502	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>				4758598	DEC 15, 1998			
>ADD>	020813	003	CLONAZEPAM;KLONOPIN	4305502	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>				4758598	DEC 15, 1998			
>ADD>	020813	004	CLONAZEPAM;KLONOPIN	4305502	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>				4758598	DEC 15, 1998			
>ADD>	020813	005	CLONAZEPAM;KLONOPIN	4758598	DEC 15, 1998			
>ADD>				4305502	DEC 15, 1998			
>ADD>				4371516	FEB 01, 2000			
>ADD>	020839	001	CLOPIDOGREL BISULFATE;PLAVIX				NCE	NOV 17, 2002
	020463	001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
>DLT>	017922	001	DESMOPRESSIN ACETATE;DDAVP	5482931	JUN 29, 2013			
				5500413	JUN 29, 2013			
				5674850	DEC 23, 2013			
				5498598	JUN 29, 2013			
>DLT>	017922	002	DESMOPRESSIN ACETATE;DDAVP	5482931	JUN 29, 2013			
				5500413	JUN 29, 2013			
				5674850	DEC 23, 2013			
				5498598	JUN 29, 2013			
>ADD>	017922	003	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>				5482931	JUN 29, 2013			
				5674850	DEC 23, 2013			
				5498598	JUN 29, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
				5674850	DEC 23, 2013			
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
				5674850	DEC 23, 2013			
	020648	001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
							ODE	JUL 29, 2004
	020648	002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
							ODE	JUL 29, 2004
	020648	003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
							ODE	JUL 29, 2004
	020648	004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
							ODE	JUL 29, 2004
	020648	005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
							ODE	JUL 29, 2004
	020037	001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
				4829088	APR 14, 2007			
	020154	002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL				NDF	DEC 08, 2000
	018723	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	019680	001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
	020623	001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
	020623	002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
	020624	001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
	020624	002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
>ADD>	020706	001	EMEDASTINE DIFUMARATE;EMADINE				NCE	DEC 29, 2002
	020668	001	ENALAPRIL MALEATE;LEXXEL	4472380	SEP 18, 2001			
				4374829	DEC 30, 2001	U-3		
	020164	001	ENOXAPARIN SODIUM;LOVENOX	4703038	OCT 07, 2005	U-3		
	020444	001	EPOPROSTENOL SODIUM;FLOLAN				I-192	MAY 06, 2000
				4335139	JUN 15, 1999			
				4539333	SEP 03, 2002			
				4883812	MAY 12, 2006	U-185		
	020444	002	EPOPROSTENOL SODIUM;FLOLAN	4338325	JUL 06, 1999			
				4539333	SEP 03, 2002			
				4338325	JUL 06, 1999			
				4883812	MAY 12, 2006	U-185		
				4335139	JUN 15, 1999			
>ADD>	020738	004	EPROSARTAN MESYLATE;TEVETEN				NCE	DEC 22, 2002
>ADD>	020738	005	EPROSARTAN MESYLATE;TEVETEN				NCE	DEC 22, 2002
	020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
				5006342	APR 09, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020683	001	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
	020683	002	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
	019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
	020457	001	ETOPOSIDE PHOSPHATE;ETOPOPHOS	RE35524	AUG 04, 2007			
	020363	001	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000
	020363	002	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000
	020363	003	FAMCICLOVIR;FAMVIR				I-207	SEP 16, 2000
	020325	001	FAMOTIDINE;PEPCID AC	4283408	OCT 15, 2000			
				5667794	MAY 02, 2015	U-205		
	019922	001	FENOLDOPAM MESYLATE;CORLOPAM				NCE	SEP 23, 2002
	020292	001	FERRIC AMMONIUM CITRATE;FERRISELTZ				NP	OCT 14, 2000
	020410	001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171	NCE	DEC 06, 2001
				5219554	JUN 15, 2010			
				4827945	MAY 09, 2006	U-170		
				4951675	SEP 13, 2005	U-169		
				5055288	OCT 08, 2008			
				4695392	SEP 22, 2004			
				4695393	SEP 22, 2004			
				4770183	SEP 13, 2005	U-169		
				5578610	NOV 26, 2013	U-192		
	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA				NC	DEC 24, 2000
>ADD>	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4357324	FEB 24, 2003			
	020038	001	FLUDARABINE PHOSPHATE;FLUDARA				NDF	NOV 07, 2000
>ADD>	020549	001	FLUTICASONE PROPIONATE;FLOVENT				NDF	NOV 07, 2000
>ADD>	020549	002	FLUTICASONE PROPIONATE;FLOVENT				NDF	NOV 07, 2000
>ADD>	020549	003	FLUTICASONE PROPIONATE;FLOVENT				NP	SEP 29, 2000
	020582	001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011			
				4589402	JUL 26, 2004	U-206		
	020582	002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		NP	SEP 29, 2000
				4589402	JUL 26, 2004	U-206		
	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F				NP	SEP 29, 2000
	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F				NP	SEP 29, 2000
>ADD>	020696	001	FOMEPIZOLE;ANTIZOL				NCE	DEC 04, 2002
>ADD>							ODE	DEC 04, 2004
	020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
				4087544	JAN 16, 2000	U-86		
	020622	001	GLATIRAMER ACETATE;COPAXONE				ODE	DEC 20, 2003
	020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	019726	001	GOSERELIN ACETATE;ZOLADEX				I-191	JUN 27, 2000
>ADD>	020305	001	GRANISETRON HYDROCHLORIDE;KYTRIL				D-36	OCT 06, 2000
>ADD>	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR				NCE	NOV 06, 2002
	020758	001	HYDROCHLOROTHIAZIDE;IRBESARTAN-HYDROCHLOROTHIAZID	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020758	002	HYDROCHLOROTHIAZIDE;IRBESARTAN-HYDROCHLOROTHIAZID	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020504	001	HYDROCHLOROTHIAZIDE;MICROZIDE				NS	DEC 27, 1999
	020729	001	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
				4743450	FEB 24, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020729	002	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
				4743450	FEB 24, 2007			
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN				NC	SEP 23, 2000
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
	020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
	020808	001	IODIXANOL;VISIPAQUE 270	5238944	AUG 24, 2010			
				5349085	SEP 20, 2011			
				4278654	JUL 03, 1999			
	020808	002	IODIXANOL;VISIPAQUE 320	4396597	JUL 03, 1999			
				5349085	SEP 20, 2011			
				4278654	JUL 03, 1999			
	020757	001	IRBESARTAN;AVAPRO	4396597	JUL 03, 1999			
	020757	002	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020757	003	IRBESARTAN;AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	040024	001	IRON DEXTRAN;DEXFERRUM	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020083	001	ITRACONAZOLE;SPORANOX	5624668	SEP 29, 2015			
	020657	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
	019927	001	KETOCONAZOLE;NIZORAL				NDF	FEB 21, 2000
	020310	001	KETOCONAZOLE;NIZORAL A-D				I-186	MAY 30, 2000
>ADD>	020811	001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE				NP	OCT 10, 2000
>ADD>	020857	001	LAMIVUDINE;COMBIVIR				NP	NOV 03, 2000
>ADD>				4828838	SEP 17, 2005		NCE	NOV 17, 2000
>ADD>				4833130	SEP 17, 2005			
>ADD>				4837208	SEP 17, 2005			
>ADD>				5047407	FEB 08, 2009			
>ADD>				4724232	SEP 17, 2005			
>ADD>				4818538	SEP 17, 2005			
	020406	001	LANSOPRAZOLE;PREVACID				I-195	JUN 17, 2000
							I-196	MAY 08, 2000
							I-197	APR 17, 2000
	020406	002	LANSOPRAZOLE;PREVACID				I-198	JUN 17, 2000
							I-195	JUN 17, 2000
							I-196	MAY 08, 2000
	020726	001	LETROZOLE;FEMARA				I-197	APR 17, 2000
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT				I-198	JUN 17, 2000
				4978672	DEC 18, 2007	U-203	NCE	JUL 25, 2002
				5631020	MAY 20, 2014			
				5631021	MAY 20, 2014			
				4954298	NOV 01, 2004			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5480656	JAN 02, 2013			
				5643607	JUL 01, 2014			
				5631020	MAY 20, 2014			
				5631021	MAY 20, 2014			
				4954298	NOV 01, 2004			
				5480656	JAN 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
				5631020	MAY 20, 2014			
				5631021	MAY 20, 2014			
				5643607	JUL 01, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	4652411	NOV 01, 2004		NP	MAR 07, 2000
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652441	NOV 01, 2004			
		5643607	JUL 01, 2014			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4677191	JUL 03, 2005		NS	MAY 30, 2000
		4728721	MAY 01, 2006		D-34	MAY 30, 2000
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652411	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5643607	JUL 01, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020580	001	LIPASE;COTAZYM					
	020448	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013		NP	DEC 09, 1999
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010		NC	JUN 26, 2000
				5612054	SEP 28, 2010			
				5489436	FEB 06, 2013			
	020641	001	LORATADINE;CLARITIN	5679376	OCT 21, 2014			
	020704	001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
				4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
	018140	001	LORAZEPAM;ATIVAN	4863931	SEP 15, 2008			
	018140	002	LORAZEPAM;ATIVAN				I-205	SEP 05, 2000
>ADD>	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN				I-205	SEP 05, 2000
	020264	001	MEGESTROL ACETATE;MEGACE				NCE	NOV 26, 2002
	019651	001	MESALAMINE;ASACOL	5338732	AUG 16, 2011			
	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				I-203	AUG 18, 2000
	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>ADD>	020868	001	METRONIDAZOLE;FLAGYL ER				NCE	MAR 03, 2000
	020743	001	METRONIDAZOLE;NORITATE				NDF	NOV 26, 2000
	020689	001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR				NP	SEP 26, 2000
	020689	002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
	020353	001	NAPROXEN SODIUM;NAPRELAN				NDF	OCT 01, 2000
	020353	002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	020353	003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	019660	001	NEDOCROMIL SODIUM;TILADE	5637320	JUN 10, 2014			
	020750	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
	020778	001	NELFINAVIR MESYLATE;VIRACEPT				NDF	OCT 01, 2000
	020779	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020381	001	NIACIN;NIASPAN	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
	020381	002	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	003	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	004	NIACIN;NIASPAN				NDF	JUL 28, 2000
	020381	005	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
	020714	001	NICOTINE;NICOTROL				NDF	JUL 28, 2000
	020592	001	OLANZAPINE;ZYPREXA				NP	MAY 02, 2000
	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5605897	FEB 25, 2014	U-176		
				4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
	019810	001	OMEPRAZOLE;PRILOSEC	5641805	JUN 24, 2014	U-184		
				4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
	019810	003	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
				4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
				5629305	FEB 04, 2014	U-188		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
				4695578	JUN 25, 2005	U-183		
				5578628	JUN 24, 2006	U-44		
	019828	001	OXICONAZOLE NITRATE;OXISTAT				I-200	AUG 18, 2000
	020262	001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198	ODE	AUG 04, 2004
				5670537	AUG 03, 2012	U-198	I-202	AUG 04, 2000
				5496804	MAR 09, 2013	U-204		
	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
							NCE	DEC 29, 1997
	019385	001	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	019385	002	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	019385	003	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
				4180582	FEB 08, 1998	U-20		
	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
	020529	001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
				5057616	OCT 15, 2008			
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
	019568	001	PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
	020279	001	PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
	020545	001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
	020545	002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
	020701	001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
				5543150	SEP 15, 2013	U-209		
	020701	002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
				5543150	SEP 15, 2013	U-209		
	020756	001	PROGESTERONE;CRINONE				NP	MAY 13, 2000
>ADD>	019151	001	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
>ADD>	019151	002	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
>ADD>	019151	003	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
	019627	002	PROPOFOL;DIPRIVAN				NP	JUN 11, 1999
	020639	001	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020639	002	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020639	003	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
>ADD>	019885	001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
>ADD>	019885	002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019885	003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
>ADD>	019885	004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
>ADD>	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA				NCE	DEC 09, 2002
	020559	001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
				5256684	OCT 26, 2010	U-199		
				5403830	APR 04, 2012	U-200		
				5407688	APR 04, 2012	U-201		
				5601848	FEB 11, 2014	U-202		
>ADD>	020741	001	REPAGLINIDE;PRANDIN				NCE	DEC 22, 2002
>ADD>	020741	002	REPAGLINIDE;PRANDIN				NCE	DEC 22, 2002
>ADD>	020741	003	REPAGLINIDE;PRANDIN				NCE	DEC 22, 2002
	020474	001	RIMEXOLONE;VEXOL	4686214	JUL 23, 2008	U-100		
	020272	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020588	001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014			
				5616587	JUN 11, 2014			
	020659	001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
				5648497	JUL 15, 2014			
	020680	001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
				5648497	JUL 15, 2014			
>ADD>	020658	001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
>ADD>				4824860	MAY 19, 2008	U-212		
>ADD>	020658	002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
>ADD>				4824860	MAY 19, 2008	U-212		
>ADD>	020658	003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
>ADD>				4824860	MAY 19, 2008	U-212		
>ADD>	020658	004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
>ADD>				4824860	MAY 19, 2008	U-212		
>ADD>	020658	005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002		NCE	SEP 19, 2002
>ADD>				4824860	MAY 19, 2008	U-212		
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
>ADD>	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-182		
>ADD>				4992474	FEB 12, 2008			
>ADD>				5225445	FEB 19, 2012	U-211		
				5380922	MAY 14, 2013			
	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020443	001	SERMORELIN ACETATE;GEREF				NP	SEP 26, 2000
							ODE	SEP 26, 2004
	020443	002	SERMORELIN ACETATE;GEREF				NP	SEP 26, 2000
							ODE	SEP 26, 2004
	019839	001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
							I-208	OCT 10, 2000
	019839	002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
							I-208	OCT 10, 2000
	019839	003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
							I-208	OCT 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019839	004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
							I-208	OCT 10, 2000
	019839	005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
							I-208	OCT 10, 2000
>ADD>	020632	001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
>ADD>				4929629	MAY 29, 2007			
>ADD>	020632	002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
>ADD>				4929629	MAY 29, 2007			
>ADD>	020632	003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		NCE	NOV 22, 2002
>ADD>				4929629	MAY 29, 2007			
	020231	001	SODIUM FLUORIDE;COLGATE TOTAL				NC	JUL 11, 2000
	020280	006	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN				ODE	OCT 31, 2004
	020280	004	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN PRESERVATIVE FREE				ODE	OCT 31, 2004
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020604	003	SOMATROPIN, BIOSYNTHETIC;SEROSTIM				NP	AUG 23, 1999
	020626	001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
	020626	002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
	020626	003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	NDF	AUG 26, 2000
>ADD>	020070	001	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
>DLT>	020070	001	TACRINE HYDROCHLORIDE;COGNEX	4816456	OCT 01, 2006	U-82		
>ADD>	020070	002	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
>DLT>	020070	002	TACRINE HYDROCHLORIDE;COGNEX	4816456	OCT 01, 2006	U-82		
>ADD>	020070	003	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
>DLT>	020070	003	TACRINE HYDROCHLORIDE;COGNEX	4816456	OCT 01, 2006	U-82		
>ADD>	020070	004	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82		
>DLT>	020070	004	TACRINE HYDROCHLORIDE;COGNEX	4816456	OCT 01, 2006	U-82		
>ADD>	020587	001	TALC;SCLEROSOL				NCE	DEC 24, 2002
	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
				4731478	OCT 27, 2004			
				4703063	OCT 27, 2004			
				4772475	FEB 27, 2006			
	020600	001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
	020600	002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
	019785	003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA				I-190	MAY 23, 2000
	020372	001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008			
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73	I-180	JAN 21, 2000
	020539	001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
	020749	001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006		NDF	OCT 17, 2000
	020646	001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
				5354760	MAR 24, 2012			
	020646	002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
				5354760	MAR 24, 2012			
	020646	003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
				5354760	MAR 24, 2012			
	020646	004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
				5354760	MAR 24, 2012			
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
>ADD>	050753	001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
	020497	001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2004	U-196	NCE	MAY 29, 2002
							ODE	MAY 29, 2004
	020136	001	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
	020136	002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
	020136	003	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
	020136	004	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
	020137	002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
				5045317	SEP 03, 2008	U-179		
	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
	020468	001	TRIAMCINOLONE ACETONIDE;NASACORT AQ				I-204	SEP 26, 2000
	074374	001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
	020719	001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004		I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004		I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020719	003	TROGLITAZONE;PRELAY	5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
				5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
	020720	001	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
				5602133	SEP 15, 2013	U-173	I-199	AUG 04, 2000
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
	020720	002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
				4572912	AUG 28, 2004		I-199	AUG 04, 2000
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
	020720	003	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164		
				5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
				5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
>ADD>	020759	001	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
>ADD>	020759	002	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
	020617	001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
	020617	002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
>ADD>	020675	001	URSODIOL;URSO				NP	DEC 10, 2000
>ADD>							ODE	DEC 10, 2004
	020487	001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
	020487	002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
							NDF	OCT 20, 2000
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
							NDF	OCT 20, 2000
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
							NDF	OCT 20, 2000
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE	DEC 28, 1998
							NDF	OCT 20, 2000
	020547	001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189		
				5583152	AUG 22, 2006			
	020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
	020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
>ADD>	020768	001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002
>ADD>	020768	002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012		NCE	NOV 25, 2002

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 80128

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

( ) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

RM301.45 .A66 1997 Nov Suppl

Approved drug products with therapeutic equivalence
C:355661 M:174736 O:12937927

ST. LOUIS COLLEGE OF PHARMACY
3 2201 90036 57

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110